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Abstract 
 
Vitamin K (VK) acts as a cofactor of the enzyme γ-glutamyl carboxylase (Ggcx) 
promoting the γ-carboxylation of VK dependent proteins (VKDP), where a 
posttranslational conversion of Glu into Gla residues is achieved, providing calcium 
binding properties to VKDPs. Some VKDPs are involved in blood clotting but also in 
other processes. During γ-carboxylation, the reduced VK is converted to the epoxide form, 
which is then recycled back into VK by the enzyme VK epoxide reductase (Vkor). 
Warfarin inhibits Vkor activity, being used to control blood clotting through the 
reduction of the γ-carboxylation of coagulation factors in patients who are at risk of venous 
thromboembolism. However, it might affect the activity of other VKDP. When 
administered during pregnancy, it induces fetal morbidity and mortality in pregnant 
women, being this associated with bleeding disorders and skeletal deformities. In this work 
the effects of VK deficiency in vertebrate’s early development were evaluated using 
zebrafish (Danio rerio) as a model. Zebrafish (embryos and larvae) were exposed to 
increasing levels of warfarin (0, 5, 25 and 125 mg L-1) during two critical periods: 0-2.5 
(embryonic development) and 2.5-5 (endotrophic larvae) days post fertilization. Larvae 
exposed to high concentrations of warfarin showed growth retardation, bleeding, 
underdeveloped swimbladder, pericardial inflammation, disruption of skeletogenesis, and 
increased mortality. The effects were much more severe when they were exposed to the 
anticoagulant during the embryonic stage. Regarding skeletogenesis, mineralization of 
several cranial structures as well as the axial skeleton was reduced. The length of the 
endochodral structures in the cranial region was also shorter in warfarin exposed larvae. 
Expression of genes involved in skeletogenesis (sox9, runx2, osx, col2a1, grp1, alp, mgp 
and bgp) was affected depending on the developmental stage analyzed. Present work 
brings new insights on the particular mechanisms by which warfarin (and thus, VK 
deficiency) affects chondrogenesis and osteoblastogenesis. 
 
 
Key-words: Vitamin K; warfarin; zebrafish; skeletogenesis; Warfarin Embryopathy; gene 
expression. 
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Resumo 
 
A vitamina K (VK) é uma vitamina lipossolúvel que atua como cofator da enzima γ-
glutamil carboxilase (Gccx) de forma a promover a γ-carboxilação das proteínas 
dependentes de VK (VKDP). Neste processo ocorre uma modificação pós-tradução que é 
responsável por converter os resíduos de glutamato (Glu) que estão presentes nas VKDP 
em resíduos γ-carboxilglutamato (Gla), que são necessários para promover a sua ligação a 
iões de cálcio de maneira a que estas possam desempenhar corretamente as suas funções. 
As VKDPs estão envolvidas na coagulação do sangue (fatores de coagulação), mas 
também em outros processos, entre os quais a esqueletogénese. Durante a γ-carboxilação, a 
forma reduzida da VK é convertida para a forma de epóxido, que é depois reciclada de 
volta para VK pela enzima VK epóxido redutase (Vkor), de maneira que esta possa ser 
novamente usada. A forma reduzida da VK tem uma elevada capacidade antioxidante e 
pode ligar-se ao recetor X de pregnano (Pxr). Através desta ligação a VK também tem um 
papel na transcrição, uma vez que o Pxr controla a transcrição de vários genes envolvidos 
tanto no processo de desintoxicação do organismo como na homeostasia óssea. 
 A Varfarina, um derivado de cumarina com baixo peso molecular é um inibidor 
da atividade da Vkor. Neste sentido, uma vez que a varfarina bloqueia a reciclagem de VK, 
esta é usada para controlar a coagulação do sangue através da redução da γ-carboxilação 
dos fatores de coagulação (e portanto a sua atividade) em pacientes que estão em risco de 
tromboembolismo venoso. A varfarina está associada a diversos problemas em humanos, 
como calcificação vascular devido à inibição da γ-carboxilação de diversas VKDP não 
relacionadas com a coagulação sanguínea, tais como a proteína Gla óssea (Bgp), a proteína 
Gla da matriz (Mgp) e a proteína rica em Gla (Grp). Vários outros anticoagulantes foram 
desenvolvidos e estão a ser testados clinicamente, contudo problemas associados a estes 
têm surgido, como é o caso do aumento do risco de infarto do miocárdio. Além disso, estes 
anticoagulantes não apresentam antidoto, sendo impossível reverter o seu efeito. Assim, 
embora a varfarina também afete a atividade de outras VKDP, continua a ser o 
anticoagulante mais eficaz e mais utilizado em todo o mundo. Quando administrada 
durante a gravidez, a varfarina tem a capacidade de atravessar a placenta induzindo 
morbilidade e mortalidade fetal em mulheres grávidas. A mortalidade fetal após exposição 
a varfarina é associada a eventos hemorrágicos e deformações esqueléticas 
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(chondrodysplasia punctata, dismorfismo facial com hipoplasia nasal, membros curtos 
entre outros), sendo esta condição patológica conhecida como embriopatia da varfarina. 
 Ao longo dos anos vários trabalhos têm demonstrado que a VK tem um papel 
importante no metabolismo do osso. Vários estudos em humano reportaram um efeito 
positivo da VK no osso, inibindo a diminuição da densidade mineral óssea e aumentando a 
resistência do mesmo. Além disso, trabalhos in vitro demonstraram que a VK está 
envolvida na promoção do crescimento e maturação osteoblástica (transição osteoblasto-
osteócito) promovendo desta forma a mineralização, mediada em parte através da γ-
carboxilação de VKDP. A VK está também envolvida na diminuição da reabsorção óssea 
(inibição da osteoclastogénese). Através da sua ligação ao recetor nuclear PXR regula 
também a homeostasia óssea, promovendo o aumento expressão de marcadores ósseos. 
Trabalhos in vivo também reforçam o papel da VK na esqueletogénese. Estudos 
verificaram que a suplementação de VK na dieta de larvas de linguado estava envolvida na 
modelação de proteínas envolvidas em vários processos biológicos, entre os quais o 
desenvolvimento ósseo, promovendo uma melhoria na qualidade da formação do osso. O 
efeito contrário foi também demonstrado; a deficiência em VK está na origem de 
distúrbios no desenvolvimento do peixe-zebra, sendo que também a esqueletogénese é 
afetada (aumento do número de deformações).  
  Neste trabalho propomo-nos a avaliar os efeitos promovidos pela deficiência em 
VK no desenvolvimento inicial de vertebrados utilizando o peixe-zebra (Danio rerio) 
como modelo. O peixe-zebra é um pequeno teleósteo de água doce que tem como 
principais características que o tornam um bom modelo de estudo a fecundação externa, a 
claridade ótica durante a embriogénese, o desenvolvimento rápido e a alta taxa de 
reprodução. Embriões e larvas de peixe-zebra foram expostos a níveis crescentes de 
varfarina (0, 5, 25 e 125 mg L-1) durante dois períodos críticos do seu desenvolvimento: 0-
2,5 (desenvolvimento embrionário) e 2,5-5 (desenvolvimento endotrófico) dias após a 
fertilização (dpf). Neste sentido, as larvas expostas a elevadas concentrações de varfarina 
(em particular a 125 mg L- 1) mostraram um atraso significativo no crescimento, eventos 
hemorrágicos, bexiga natatória subdesenvolvida, inflamação pericárdica, reabsorção do 
saco vitelino afetada e perturbação na esqueletogénese (mineralização e comprimento 
ósseo), levando a um aumento significativo da mortalidade. Os efeitos encontrados foram 
muito mais graves quando o peixe-zebra foi exposto ao anticoagulante durante a fase 
embrionária, sendo que estas larvas mostraram imitar a embriopatia da varfarina em 
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humanos. Quanto à esqueletogénese, verificou-se que a mineralização de várias estruturas 
cranianas (tais como o basioccipital, o opérculo, o cleitro, os arcos ceratohiais e o 
parasphenoide), bem como o esqueleto axial se encontrava reduzida. O comprimento das 
estruturas endocondrais na região craniana (cartilagem de Meckel, arcos ceratohiais, o 
primeiro arco ceratobranquial e a placa etmoide) também foi encontrado reduzido em 
larvas expostas a varfarina. A expressão de genes envolvidos na esqueletogénese (sox9, 
runx2, osx, col2a1, grp1, alp, mgp e bgp) foi também encontrada afetada, sendo que a 
alteração na expressão dependeu do estágio de desenvolvimento em que a análise foi feita. 
Enquanto aos 3 dpf as larvas expostas à varfarina mostraram uma alteração na expressão 
(subexpressão) em genes envolvidos na condrogénese (sox9, col2a1 e grp1), aos 5 dpf a 
expressão de genes envolvidos na osteoblastogénese (osx e alp) foi encontrada alterada 
(subexpressão). Surpreendentemente, alguns genes envolvidos tanto na condrogénese 
como na osteoblastogénese (runx2 e osx) foram encontrados sobre-expressos aos 16 dpf 
nas larvas expostas à varfarina, indicando um desenvolvimento tardio do esqueleto. 
 Neste sentido, o presente estudo traz novas visões em particular sobre os 
mecanismos pelos quais a varfarina (e portanto, a deficiência em VK) afeta tanto a 
condrogénese como a osteoblastogénese. Este estudo reforça também o importante papel 
que a VK tem no desenvolvimento inicial dos vertebrados.  
 
Palavras-chave: vitamina K; varfarina; peixe-zebra; esqueletogénese; Embriopatia da 
varfarina; expressão génica. 
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1. Introduction 
 
1.1 Skeleton: functions, tissues and cell types 
The skeleton, formed mainly by bone and cartilage, plays important functions in the 
organism providing internal support and protection to vital organs. Further, together with 
the musculature it allows the locomotion. In mammals, bone is also a source of calcium 
and phosphate under specific conditions and holds the house of the hematopoietic system 
(reviewed in Hall, 2015). 
Cartilage, unlike bone, is an avascularized and anaerobic tissue consisting of cells 
in an extracellular matrix (ECM; reviewed in Hall, 2015). Cartilage cells are generally the 
chondroblasts and the chondrocytes (cartilage forming and homeostasis), which are 
derived from mesenchymal stem cells, being responsible to secrete a cartilaginous ECM 
(Myllyharju, 2014). ECM in cartilage is composed by specific types of collagens, 
glycosaminoglycans (GAGs), proteoglycans and water. The major collagen is the type II, 
however other collagen types, such as VI, IX and XI are present. In particular hypertrophic 
chondrocytes are characterized by the production of type 10 collagen. Regarding to 
proteoglycans, aggrecan is the major component (Myllyharju, 2014).  
Bone is an aerobic and vascularized tissue consisting of cells and an ECM. The 
main bone cell types are the osteoblasts (bone-forming cells), the osteocytes (bone 
homeostasis), and the osteoclasts (bone remodeling). Osteoblasts are cells derived from 
mesenchymal stem cells and are responsible for synthetizing the ECM. When they become 
trapped into ithe ECM, they are called osteocytes (Franz-Odendaal et al., 2006). 
Osteocytes are osteoblast-derived cells involved in bone homeostasis, regulating some 
bone responses to particular stimulus, such as damages and mechanical loads. Osteocytes 
can communicate with neighboring osteocytes and with the other cells on the bone surface 
via canaliculi within the bone matrix. Through this communication, osteocytes are 
involved in the regulation of the deposition of bone matrix, modulation of osteoclast 
activity, but also in the resorption of the perilacunar bone (osteocytic osteolisys; reviewed 
in Hall, 2015). They are by far the most abundant cellular component of bones, making up 
95% of all bone cells (Franz-Odendaal et al., 2006).  Interestingly, bone can be classified 
by the presence or absence of osteocytes in the ECM, so in this sense, bone may be cellular 
(osteocytic) or acellular (anosteocytic; reviewed in Hall, 2015). Finally, osteoclasts are 
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mono or multinucleated cells of hematopoietic origin responsible for bone remodeling 
(Witten et al., 2001; Boyle et al., 2003). The mature osteoclasts are activated by external 
signals like the activation of receptor activator of nuclear factor kβ (RANK) by its ligand 
RANKL inducing internal structural changes to prepare them for bone resorption. In this 
sense, rearrangements of the actin cytoskeleton and formation of a tight junction between 
the bone surface and basal membrane form a sealed compartment which is then acidified 
by the export of hydrogen ions (Boyle et al., 2003). Secretion continues with the export of 
the lytic enzymes Tartrate-resistant acid phosphatase (TRAP) and pro-cathepsin K into a 
resorption pit called as Howship’s lacunae (Boyle et al., 2003). In contrast to cartilage 
ECM, bone ECM is composed essentially by inorganic components (65%-70% of total 
ECM) such as calcium and phosphate but also by organic components (35%-30% of total 
ECM) such as collagen fibers (mainly type I collagen) and other non-collagenous proteins 
such as proteoglycans, growth factors, and other bone matrix proteins, such as bone Gla 
protein (Bgp), osteopontin, osteonectin and matrix Gla protein (Mgp; reviewed in Jiang et 
al., 2007; Hall, 2015).  The first bone matrix is formed in an unmineralized state, known as 
osteoid, being then impregnated with hydroxyapatite to form bone (Hall, 2015).  
 
1.2 Bone formation and mineralization 
Bone can form through two different processes. In one hand, most of the mammalian 
skeleton is formed by endochondral ossification, which involves a cartilage intermediate. 
 In this process mesenchymal stem cells form condensations and differentiate into 
chondroblasts (Fig. 1.1A; Crombrugghe et al., 2001). Bone growth occurs through a 
specialized cartilaginous structure, named growth plate, where an ordered zone of 
proliferating and differentiating chondrocytes produce the extracellular matrix (Fig. 1.1B; 
Myllyharju, 2014). These chondrocytes undergoing unidirectional proliferation become 
hypertrophic and start to mineralize the ECM before entering in apoptosis (Fig. 1.1C; 
Crombrugghe et al., 2001). At the same time that chondrocyte hypertrophy occurs, some of 
the mesenchymal stem cells surrounding cartilage start to differentiate leading to the 
appearance of osteoblasts (Fig. 1.1D). These osteoblasts invade the zones of hypertrophic 
chondrocytes together with blood vessels and osteoclasts (Fig. 1.1E). While osteoclasts 
degrade the hypertrophic cartilage matrix, osteoblasts use the remnants of cartilage matrix 
as a scaffold for the deposition of bone matrix (Crombrugghe et al., 2001). 
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On the other hand, a small number of skeletal elements, mainly craniofacial and flat 
bones, are formed by intramembranous ossification. Here, bones form through 
mesenchymal stem cell condensations that differentiate directly into osteoblasts, without a 
cartilage template (Crombrugghe et al., 2001). 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. General illustration of the endochondral ossification process. Cells in the condensations 
differentiate into chondrocytes (A-B). These chondrocytes undergo unidirectional proliferation, becoming 
hypertrophic (C). At the same time that chondrocyte hypertrophy occurs, some of the mesenchymal cells 
surrounding cartilage start to differentiate into osteoblasts (D). These osteoblasts invade the zones of 
hypertrophic chondrocytes together with blood vessels and osteoclasts (E). Figure adapted from 
http://www.anatomiahumana.ucv.cl/kine1/top2.html. 
 
1.3 Transcriptional control of bone formation and homeostasis 
Early development of the skeleton is dependent on factors which have crucial roles in the 
cell-fate process by which mesenchymal cells become chondrocytes and osteoblasts (Fig. 
1.2; reviewed in Sinha and Zhou, 2013). These are transcription factors (TF) and nuclear 
receptors (NR). TFs are proteins that can bind to specific DNA sequences, thereby 
controlling the rate of transcription of genetic information from DNA by promoting or 
blocking the transcription of specific genes (Latchman, 1997; Lee and Young, 2000). NRs 
are transcription factors that respond to signals carried by steroids, thyroid hormones and 
other molecules such as vitamins. Through this interaction they are able to regulate the 
expression of specific genes by its binding to specific DNA sequences (reviewed in Huang 
et al., 2010). Some TFs important in bone formation will be described (Runx2, Sox9 and 
Osterix) as well as NRs such as the pregnane X receptor (Pxr), a nuclear receptor involved 
in bone homeostasis (Azuma et al., 2010). 
A B C D E 
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Sex determining region Y-box 9 (Sox9) is a member of the TFs Sox family, being 
required for testogenesis, chondrogenesis, terminal differentiation of oligodendrocytes and 
cardiogenesis (Mori-Akiyama et al., 2003 Akiyama, 2008). Regarding its role in 
chondrogenesis, Sox9 is crucial for the commitment of osteochondroprogenitors, 
chondrogenic mesenchymal condensation and proper chondrocyte proliferation, 
differentiation, maturation and hypertrophic conversion (Akiyama, 2008). During 
embryogenesis it is expressed in all chondroprogenitors and chondrocytes, except in the 
hypertrophic (Akiyama, 2008). Studies have showed that Sox9-null cells do not express 
chondrogenic marker genes, such as col2a1, col9a2, col11a2, and aggrecan (Akiyama, 
2008). Further, mutations in one allele of Sox9 in humans result in campomelic dysplasia 
(CD), a skeletal dysplasia characterized by sex reversal and skeletal malformations of 
endochondral bones (Mori-Akiyama et al., 2003; Akiyama, 2008). 
The runt-related TFs family includes Runx1, Runx2 and Runx3. These factors are 
essential for hematopoietic (Runx1), neuronal, gastrointestinal (Runx3) and 
osteochondrogenic (Runx2) differentiation (reviewed in Ziros et al., 2008). In particular 
Runx2, also known as core-binding factor alpha 1 (Cbfa1) is essential in the terminal 
differentiation of chondrocytes, a prerequisite for endochondral ossification. During 
osteoblast differentiation, Runx2 play essential roles in the commitment of pluripotent 
mesenchymal cells to the osteoblastic lineage (reviewed in Komori, 2010). There are two 
known isoforms of Runx2. The type I seems to be mainly involved in intramembranous 
bone formation (reviewed in Ziros et al., 2008). The type II isoform is exclusively involved 
in endochondral bone formation. Runx2 operates by binding to osteoblast-specific cis-
acting element 2 (OSE2), which is found in the promoter region of all major osteoblast-
related genes (reviewed in Ziros et al., 2008). Studies have demonstrated that mice with a 
mutated runx2 locus have a complete lack of ossification due to the maturational arrest of 
osteoblasts (reviewed in Ziros et al., 2008).  
Like Runx2, Osterix (Osx; also known as Sp7 TF) is a major and essential effector 
for osteoblast differentiation, activating bone-specific genes that support bone formation 
(reviewed in Shina and Zhou, 2013). Mice lacking Osx die within 1 h of birth with a 
complete absence of intramembranous and endochondral bone formation (Baek et al., 
2009). 
Pxr (also known as steroid and xenobiotic receptor; SXR) is a member of the NR 
superfamily NR1I, it is mainly expressed in the liver and intestine where it acts as a 
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xenobiotic sensor. In fact, it plays important roles on different processes like the 
detoxification of the organism (drug metabolism), bone homeostasis, but also regulating 
metabolic pathways for the elimination of cholesterol and regulating the glucose 
metabolism (Timsit and Negishi, 2007). Pxr can be activated by various endogenous and 
dietary substances such as vitamin K (VK), pharmaceutical agents and xenobiotic 
compounds (Ekins et al., 2008). Recently, Wallace et al. (2013) described the 3D structure 
the heterodimer formed by Pxr and the retinoid X receptor (Rxr). The formed complex will 
bind to Sxr responsive elements (Sxre) in the promotor or enhancer regions of target genes, 
activating their transcription. Although expression of pxr was detected at lower levels in 
bone, being found in osteoblasts (Tabb et al., 2003; Azuma et al., 2010); Azuma and 
colleagues (2010) have demonstrated that systemic Pxr deficiency results in osteopenia. 
They also saw through histomorphometrical analysis of trabecular bones that bone 
formation parameters (bone mineral density and stiffness) were decreased in pxr knock-out 
compared with WT mice, suggesting Pxr loss-of-function result in suppressed osteoblastic 
function (Azuma et al., 2010). Pxr also affected calcium and phosphate homeostasis 
through the induction of vitamin D-catabolizing enzyme CYP3A4 in the liver and intestine 
(Zhou et al., 2006). VK2, according to Tabb et al. (2003), can have important roles in bone 
development by binding to Pxr, through the regulation of the transcription of bone markers 
such as alp, mgp and opn. Further characterization of how VK2 induce osteoblast function 
through Pxr at transcriptional level of other osteoblastic genes (tsukushi, matrilin-2 and 
CD14 antigen) was reported by Ichikawa et al. (2006). In addition, other possible pathways 
by which Pxr affect bone metabolism can be the suppression of the nuclear factor kappa-B 
(NF-kB) signalling (Gu et al., 2006). NF-kB was reported as a promoter of 
osteoclastogenesis (Jimi et al., 2004) and inhibitor of bone formation by mature osteoblast 
(Chang et al., 2009). 
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Figure 1.2. Transcriptional roles of Sox9, Runx2 and Osx in the cell-fate process by which mesenchymal 
cells become chondrocytes and osteoblasts. Sox9 is crucial for the commitment of osteochondroprogenitors, 
chondrogenic mesenchymal condensation and proper chondrocyte proliferation, differentiation, maturation 
and hypertrophic conversion. Runx2 is essential for chondrocyte and osteoblast differentiation. Osx, together 
with Runx2, is essential for osteoblast differentiation and function. Figure modified from Karsenty, 2008. 
 
1.4 Vitamin K 
Vitamin K (VK) belongs to the group of fat-soluble vitamins, being only de novo 
synthesized by plants and bacteria. There are two natural metabolites, phylloquinone (VK1) 
and menaquinone (VK2), and a synthetic one, menadione (VK3; Oldenburg et al., 2008). 
VK1 is synthesized by plants while VK2 or menaquinones (MK) are synthesized by a 
limited number of obligate and facultative anaerobic bacteria, some of which occupy the 
microflora of the human gut (reviewed in Shearer and Newman, 2014). The MK family 
contains a wide spectrum of isoprenologs being named according to the number of these 
prenyl units (MK-n; reviewed in Shearer and Newman, 2014). VK is predominantly 
present in the forms of VK1 and menaquinone-4 (MK-4), which is now known to be 
synthesized in human from VK1 by the UbiA prenyltransferase containing 1 (Ubiad1) 
enzyme (Ferland, 2012).  
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VK in lower organisms has an important role as electron carrier in energy 
transduction pathways (Oldenburg et al., 2008). In contrast, in higher organisms, the VK 
family members have been studied during decades due to its important role on blood 
coagulation process (Oldenburg et al., 2008). In this sense VK acts as cofactor of the γ-
glutamyl carboxylase (Ggcx) enzyme, which is responsible to perform posttranslational γ-
carboxylation of vitamin K dependent proteins (VKDPs). VK (reduced form VKH2) was 
also recognized as having a potent antioxidant capacity (Mukai et al., 1993; Fig. 1.3).Also 
Li et al. (2003) had demonstrated that cell death caused by oxidative stress can be 
prevented in cultures of neuronal cells by VK1 and VK2 through the blockage of reactive 
oxygen species (ROS) accumulation.  More recently, Westhofen et al. (2011) suggested 
that one of the enzymes responsible for VK recycling, Vitamin K epoxide reductase 
complex subunit 1-like protein 1 (Vkorc1l1), is responsible for VK-mediated increased 
survival of cells under oxidative stress limiting the amount of intracellular ROS in vitro. In 
addition, VK was identified as a specific ligand of Pxr (Tabb et al., 2003; Fig. 1.3). In this 
sense therefore, VK also have a transcriptional role, controlling different pathways through 
its binding to this nuclear receptor (Tabb et al., 2003).  
Beside the roles above described, VK is also important in sphingolipid metabolism. 
VK promotes the induction of 3-ketodihydrosphingosine synthase (3-KDS), the enzyme 
involved in the initial step of sphingolipid biosynthesis (reviewed in Ferland, 2012). 
Sphingolipids are a group of complex lipids present in cells, being the major components 
of cell membranes (reviewed in Ferland, 2012), and are viewed as crucial players of 
important cellular events such as proliferation, differentiation, senescence and cell–cell 
interaction (reviewed in Ferland, 2012).  
 
1.5 Vitamin K cycle  
In mammals, recycling of VK (Fig. 1.3) is extremely important, since VK reservoirs in the 
organism are low. As described before, VK plays important roles, such as acting as a 
cofactor to the Ggcx enzyme, which is responsible for the posttranslational modification of 
glutamate (Glu) to γ-carboxylglutamate (Gla) required for the activity of VKDPs, 
conferring them calcium binding properties (reviewed in Stafford, 2005; Oldenburg et al., 
2008). The γ-carboxylation reaction requires the propeptide-containing substrate and three 
co-substrates: reduced VK (reduced form, VKH2), CO2 and O2. The rate of γ-carboxylation 
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is mainly controlled by the level of VKH2 available for the reactions; while the dissociation 
rate constant is dependent upon both the propeptide and the Gla domain of the substrate. 
To promote the γ-carboxylation the subtraction of a proton from the carbon 4 of glutamate 
by VKH2 is required, and results in the conversion of VKH2 to VK epoxide. The epoxide 
form must be recycled to VK before it can be reused, a reaction catalyzed by the enzyme 
vitamin K epoxide reductase (Vkor; reviewed in Stafford, 2005). In contrast to genomes of 
archaea, eubacteria, plants, protists, and lower animals that include a single Vkor protein, 
the vertebrate genomes include two paralogous enzymes, Vitamin K epoxide reductase 
complex subunit 1 (Vkorc1) and Vitamin K epoxide reductase complex subunit 1-like 
protein 1  (Vkorc1l1; Westhofen et al., 2011). Westhofen et al., (2011) suggested that both 
enzymes have different functions; Vkorc1 is responsible for converting the epoxide in VK, 
being then Vkorc1-like 1 responsible for reducing the VK to its active form (VKH2; 
Westhofen et al., 2011). That author suggests that Vkorc1 is more efficient at de-
epoxidation (Vkor activity), whereas Vkorc1l1 is more efficient at converting quinone to 
hydroquinone reduction (VKR activity; Westhofen et al., 2011). However, Hammed et al. 
(2013) showed recently that Vkorc1l1 is also able to support Vkor activity and can be an 
alternative pathway able to substitute or partially complement for loss of Vkorc1 function 
in various non-hepatic tissues of vkorc1 knockout mice. Thus, it seems that both enzymes 
are able to support Vkor and VKR activity, being responsible for de novo reduction of VK 
in the VK cycle (Oldenburg et al., 2015). 
Although VK recycling is crucial to restore the levels of this vitamin available in 
organisms, it can be blocked by some anticoagulants (coumarins), which are specific 
inhibitors of Vkor activity and called as vitamin K antagonists (VKA; Fig. 1.3). 
Anticoagulant therapy is particularly recommended to prevent and treat thromboembolic 
conditions in patients who have prosthetic heart valves but also with history/symptoms of 
excessive levels of blood coagulation (How, 2004; Moyer et al., 2009). Commonly are 
used those comprising parenteral anticoagulants, such as unfractionated heparin, low-
molecular-weight heparin or fondaparinux, but also VKA such as warfarin, acenocumarol 
or phenprocoumon (coumarin derivatives; Beinema et al., 2008; Gómez-Outes et al., 
2009). Other anticoagulants have been recently developed, such as dabigatran, 
rivaroxaban, apixaban, edoxaban or betrixaban (Gómez-Outes et al., 2013). However, this 
new molecules are more problematic anticoagulant therapies, since in general they 
(specifically targeting Thrombin and FXa) have no antidote (Gómez-Outes et al., 2013). In 
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addition, other particularities have been described, such as an increase of myocardial 
infarction risk when patients are under Dabigatran therapy (Kohli and Cannon, 2013). 
Nowadays, the most used anticoagulant is warfarin (3-(a-acetonylbenzyl)-4-
hydroxycoumarin). Warfarin is a low molecular weight drug derived from coumarins being 
a racemic mixture of R and S enantiomers, with the S enantiomer being about three times 
more potent than the R enantiomer (Kamali and Wynne, 2010). Since it acts as VKA, this 
effect is used in oral anticoagulation treatments for thromboembolic disorders, controlling 
the γ-carboxylation of coagulation factors (Oldenburg et al., 2008). In this way, warfarin 
therapy leads to a decrease on the activity of the clotting factors II, VII, IX, and X, as well 
as the naturally endogenous anticoagulant proteins C and S, leading to a decrease on blood 
coagulation rate (Kuruvilla and Gurk-Turner, 2001). However, although warfarin treatment 
has been successfully used to control thromboembolic disorders, undesired side effects 
such as bleeding, swelling, bruising, articular pain or skin conditions have been reported as 
warfarin also prevents the γ-carboxylation of other VKDPs and might hamper the 
transcriptional activity of Pxr (Fernandez et al., 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Vitamin K cycle and its metabolic and transcriptional roles. VK coming from dietary intake or 
glut microflora is first transformed to VKH2 (reduced form has the antioxidant capacity). In one hand VKH2 
is used by the γ-glutamyl carboxylase (Ggcx) to convert glutamate into γ-carboxyl glutamate (Gla) residues 
in VK-dependent proteins; as a by-product VK epoxide. VK epoxide is then recycled to VK quinone by VK 
epoxide reductase (Vkor). VKH2 is also involved in the antioxidant activity. Warfarin is a known inhibitor of 
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the VK recycling through its binding to Vkor. At the other VK is a ligand of the nuclear receptor Pxr. The 
activation of Pxr by VK, promote the formation of a heterodimer with retinoid acid receptor (Rxr). Then the 
formed complex will bind to Sxr responsive elements (Sxre) in the promotor or enhancer regions of target 
genes, activating their transcription and thus proteins synthesis. 
 
 
 
1.6 VK deficiency 
During pregnancy, anticoagulant therapy is recommended to women who use prosthetic 
heart valves and have thromboembolic conditions but also with history/symptoms of 
excessive levels of blood coagulation (How, 2004). However, this is problematic because 
since warfarin has a low molecular weight, it can pass through the placenta inducing 
spontaneous abortion, stillbirth, neonatal death, and a variety of congenital anomalies 
known as fetal warfarin syndrome (FWS) or warfarin embryopathy (WE; How, 2004; 
Sathienkijkanchai and Wasant, 2005). In WE the warfarin’s teratogenic effects can occur 
when the fetus is exposed during either in embryonic (since fertilization until 8ª week) and 
fetal period (from 9ª week until the birth; Hou, 2004). However, the most critical period is 
between 6-9 weeks of gestation (reviewed in Sathienkijkanchai and Wasant, 2005). The 
effects comprise a wide range of manifestations such as dysmorphology in neonate with 
chondrodysplasia punctata (nasal hypoplasia and stippling of epiphyses), spine 
abnormalities, choanal atresia, laryngeal abnormalities, short neck, hypoplasia of distal 
phalanges, brachydactyly, short limbs and less frequently, abnormalities of the brain, eyes, 
and ears (Menger et al., 1997; Sathienkijkanchai and Wasant, 2005; Mehndiratta et al., 
2010). Other manifestations in fetuses exposed to warfarin after the second or third 
trimester include optic atrophy, blindness, corneal opacity, deafness, microcephaly, 
hydrocephalus, epilepsy and mental retardation (reviewed in Sathienkijkanchai and 
Wasant, 2005).  
Others conditions related with a deficiency of VK are known such as VK 
deficiency bleeding (VKDB) and VK deficiency embryopathy (Sutor et al., 1999; Shearer, 
2009). VKDB is an acquired coagulopathy caused by a reduction of VK dependent 
coagulation factors below homeostatic levels, which is associated to intracranial 
hemorrhages in infants (Sutor et al., 1999; Shearer, 2009). VK deficiency embryophaty is a 
condition caused by a prenatal disorder in the VK metabolism, which is considered a 
phenocopy of WE (Menger et al., 1997). These conditions can be triggered by insufficient 
intake of VK, decreased gut flora, decreased VK absorption, or disruption of VK recycling 
Zebrafish as a model of warfarin embryopathy        Chapter 1 
12 
 
caused by mutations in Vkor and/or inhibited γ-carboxylation due to mutations in Ggcx 
enzymes (Menger et al., 1997; Greer, 2010; Takada et al., 2014). Several studies have 
demonstrated that mutations in Ggcx are responsible for visceral hemorrhages and a short 
life span (Zhu et al., 2007). Regarding to mutations in Vkor, Spohn et al., (2009) have 
demonstrated that homozygous Vkorc1-deficient mice developed normally until birth, but 
dyeing within 2-20 days after birth due to extensive, predominantly intracerebral 
hemorrhage resulted from a severe deficiency of γ-carboxylated clotting factors. 
Although some information regarding the roles of VK and the signaling pathways 
controlled by Pxr at transcriptional level are known, the specific signaling pathways by 
which warfarin therapy during pregnancy induce WE in newborns is still not known. 
 
1.7 Zebrafish 
Animal models in biomedical research have been used to understand the mechanisms 
underlying vertebrate’s development and pathogenesis of human diseases. In this sense, 
zebrafish (Danio rerio) has emerged as an excellent animal model, taking advantage over 
other ones, such as rodents and other mammalian species (reviewed by Lieschke and 
Currie, 2007). Zebrafish is a small freshwater teleost, with external fertilization, optical 
clarity during embryogenesis, rapid development, high reproductive rate and short life 
cycle. In addition, in the last years, genomic resources have been developed, including 
high density genetic maps for mapping induced mutations (Lieschke and Currie, 2007). In 
this sense, although zebrafish has been used mainly for developmental and molecular 
biology studies, teleosts are also suitable models for studying vertebrate skeletogenesis for 
both comparative (Witten and Huysseune, 2009) and evolutionary (Sire et al., 2009) 
purposes. Furthermore, zebrafish is a reliable tool in toxicology research as well as in drug 
discovery (Lieschke and Currie, 2007).  
Previous works have demonstrated the expression and activity of Ggcx and its 
inhibition by warfarin exposure in zebrafish (Hanumanthaiah et al., 2001) and its 
teratogenicity and embryonic lethality under acute warfarin exposure (Weigt et al., 2012). 
Fernández et al., (2014) have characterized the effects of warfarin’s long-term exposure 
during zebrafish exogenous feeding phase, and highlighted the two major up-stream 
pathways by which warfarin might affect normal development (VK-dependent protein γ-
carboxylation rate and Pxr activation). More recently, Fernández et al., (2015) have 
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demonstrated that opposite VK status (induced VK deficiency by warfarin exposure and 
VK supplementation) was correlated with the altered expression of some of the molecular 
players of the VK cycle in vitro. The same authors also reported the gene expression 
patterns of vkors throughout larval development and in adult tissues in fish. Altogether 
indicate that zebrafish might be a good model to uncover the detailed mechanisms by 
which warfarin exposure during early development induce WE. 
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2. Objectives 
 
The present study aimed at describing the effects of an induced VK deficiency through 
warfarin exposure in skeletogenesis and unveils the affected underlying skeletogenic 
pathways. Previous works have described the effects of an induced VK deficiency in 
zebrafish early development upon warfarin exposure. However, no reports have 
demonstrated the effects of VK deficiency in the skeletal development. In this work the 
effects of this deficiency in larval performance and skeletogenesis in zebrafish larvae 
exposed to warfarin during two critical periods of its development (0-2.5, embryonic stage; 
and 2.5-5 days post fertilization (dpf), endotrophic stage) will be evaluated. Larval 
performance, mineralization degree of the skeleton, skull structures length and gene 
expression of osteogenic markers will be analyzed at specific time points. 
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3. Materials and methods 
 
3.1 Embryos rearing and fish maintenance  
Zebrafish eggs were obtained from natural pairwise mating of wild type broodstock 
maintained in a ZebTec housing system (Tecniplast), being then collected and distributed 
in petri dishes (65-75 eggs per dish). Water parameters were maintained as follows: pH 7.6 
± 0.2; 700 mS conductivity; 7.8 mg L-1 dissolved oxygen; 14:10 hours light:dark 
photoperiod. In order to determine the effects of warfarin during the two key early 
developmental stages (embryonic and larval endogenous feeding phase), embryos or larvae 
were exposed to increasing concentrations of this VKA (0, 5, 25, 125 mg L-1; named as 
Control, W5, W25, and W125, respectively) from 0 to 2.5 days post fertilization (dpf; 
embryonic development) and from 2.5 to 5 dpf (corresponding from hatching to mouth 
opening; endotrophic developmental stage; Fig. 3.1) in triplicate. After warfarin exposure, 
larvae were transferred to 500 ml tanks and raised until 16 dpf. From 4 dpf to the end of 
the trial zebrafish larvae were fed twice a day with newly hatched Artemia nauplii (AF 
strain INVE, 5-10 nauplii mL-1), and a 50% water renewal every two days was done.  
   
Figure 3.1. Schematic representation of zebrafish exposure to warfarin. Zebrafish embryos and larvae 
were exposed to increased levels of warfarin: 0 (Control), 5, 25 and 125 mg L-1 during embryonic and 
endotrophic stages. After warfarin exposure larvae were raised until 16 dpf.  
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3.2 Compound exposure 
Warfarin (3-(α-acetonylbenzyl)-4-hydroxycoumarin sodium salt; Sigma-Aldrich) was 
dissolved in distilled water. Work solutions (5, 25 and 125 mg L-1) were prepared for 30 ml 
of water from a stock of 10 mM. 
 
3.3 Fish sampling 
Fish from the different experimental groups were sampled at 3, 5, 7 and 16 dpf. Larvae 
were euthanized with a lethal dose of tricaine methanesulfonate (MS-222, Sigma-Aldrich) 
and washed with sterilized water. Larvae were then fixed in 1 ml of paraformaldehyde 
(PFA) 4% (pH 7.4), during 2h at room temperature (RT) and stored in 1ml of 100% 
ethanol (EtOH) until double staining procedure was performed, or in 1ml of TRIzol 
reagent (Qiagen) at -80 °C until RNA extraction. 
 
3.4 Larval performance 
Survival rate was calculated as the percentage of surviving fish at the end of the trial with 
respect to the initial number of fish minus the sampled larvae during embryonic or 
exogenous feeding larvae trials, respectively. Standard length of larvae, presence of 
hemorrhages, swimbladder inflation/development degree, pericardial aedema, yolk sac 
appearance and general larval morphology were evaluated under an MZ7.5 
stereomicroscope (Leica Microsystems). 
 
3.5 Skeletal development 
In order to analyze the particular effects of warfarin exposure on the skeletal development 
and incidence of skeletal deformities, a modified whole amount alcian blue-alizarin S red 
double staining technique for bone and cartilage staining from Walker and Kimmel (2007) 
at 5, 7 and 16 dpf larvae was used (described in detail below). After staining, the skeletal 
development (percentage of structures non-, slightly- and mineralized) of cranial 
(basioccipital (bop), ceratohyal arches, ceratobranchial arches, cleithrum, operculum, 
parasphenoid) and axial structures (weberian, precaudal, vertebrae, fin vertebrae) was 
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assessed under a MZ7.5 stereomicroscope (Leica Microsystems). Skeletal structures were 
named according to Bird and Mabee (2003). 
 
3.6 Whole mount double staining procedure 
A modified whole mount alcian blue-alizarin S red double staining technique was used to 
stain larvae from 5, 7 and 16 dpf. In brief, after larvae were fixed with PFA (4% and pH 
7.4), during 2 hours at RT, they were dehydrated in EtOH through a graded series of EtOH 
in water (25, 50, 75 and 100% v/v), during 10-30 minutes each. For the cartilage staining 
of the samples, they were treated with alcian blue Solution 0.02% (Stock solution 0.4%) 
with 80 mM chloride magnesium (in 70% EtOH) during 10-12 hours.  
For bone staining, the samples were treated with a 0.005% alizarin red S solution in 
water for 1 hour (Stock solution 0.5%). Subsequently, larvae were bleached during at least 
1 hour with a 1.5% hydrogen peroxide (H2O2) and 1% potassium hydroxide (KOH) 
solution. Finally, clearing of larvae to remove the excess of dye in soft tissues was done 
with 20% glycerol and 0.25% KOH solution for 4 hours, 50% glycerol and 0.25% KOH 
overnight (ON) at 4° C, 50% glycerol in water and 75% glycerol in water ON at 4 °C. 
Larvae were then stored in 100% glycerol at 4 °C. After staining, the mineralization status 
of the skeletal structures was evaluated. 
 
3.7 Morphometric analysis 
Cranial structures, such as meckel´s cartilage, ceratohyal, the first ceratobranchial arch and 
ethmoid plate were measured (length and width) as depicted in Figure 3.2. For this 
purpose, cranial structures of larvae previously double stained were manually dissected 
under a Stereo Discovery.V20 stereomicroscope (Zeiss) and placed in microscope slides. 
The structures were then photographed (AxioCam) in an Axio Imager.Z2 microscope 
(Zeiss) and analyzed using AxioVision image software.  
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Figure 3.2. Schematic representation of the dissected and measured cranial structures in zebrafish larvae. 
Structures from the lower jaw, Meckel´s cartilage (1), ceratohyal arches (2), the first ceratobranchial arch (3; 
A) and from the upper jaw, ethmoid plate length (4), width (5) and angle (6; B) were measured in larvae 
exposed to increased levels of warfarin: 0 (Control), 25 (W25) and 125 mg L-1 (W125) during embryonic and 
larval stage. Scale = 100 µm. 
 
3.8 RNA extraction 
Total RNA was extracted from samples using TRIzol reagent (QIAGEN) as specified by 
the manufacturer. Briefly, samples were homogenized using seringes (18 and 20 G; 
TERUMO). The homogenate was then kept at room temperature (RT) during 5 minutes. 
After this step, phenol-chloroform (0.2 ml per ml of TRIzol) was added and vigorously 
agitated and kept at RT during 3 minutes. Samples were then centrifuged at 12000g, 4 °C 
during 15 minutes. At the end of this step three different phases were obtained. The upper 
aqueous phase (containing RNA) was passed to a new tube and subsequently isopropanol 
(0.5 ml per ml of TRIzol) was added. Tubes were then vortexed and incubated at RT 
during 10 minutes. A new centrifugation step was performed at 12000g, 4 °C during 10 
minutes. The resulting supernatant was then removed and EtOH 75% was added (1 ml of 
75% EtOH per ml of Trizol) to wash the pellet. A new centrifugation (7500g at 4 °C 
during 5 minutes) was done and EtOH 75% was removed. Diethylpyrocarbonate (DEPC) 
treated water (30 µL for first sampling points (3 and 5 dpf) and 100 µL for 16 dpf sampling 
1 
2
3
4 
5 
6 
A B 
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point) was added to eppendorfs and warmed (at 55 ºC) until RNA was dissolved. RNA 
quantification was determined measuring the optical density at 260 nm, using a Nanodrop 
(Thermo Scientific). Purity of RNA was established by the absorbance ratios 260/280 nm 
and 260/230 nm. 
 
3.9 DNAse treatment and cDNA synthesis by Reverse Transcription (RT) reaction 
The synthesis of cDNA was performed using the Moloney-murine leukemia virus (M-
MLV) reverse transcriptase (200U/µL, Invitogen), according to manufacturer protocol. 
Briefly, RNA samples were treated with DNAse (RQ1 RNase-Free DNase; Promega). 
Next, the reaction was incubated for 10 minutes at 65 ºC. 500 ng of total RNA was 
supplemented with 1 µL oligo(dT) (500 µg/ml; Sigma-Aldrich) 1 µL dNTP’s (10 mM, 
Invitrogen),  4 µL of First Strand buffer (5x, Invitogen) and 1 µL of DTT (0.1 M). This 
mixture was incubated during 3 minutes at 60 ºC, and then cooled 5 min at 4 ºC. To the 
resulting reaction 1 µL RNaseOUT (40U/µ, Invitrogen) and 1 µL of M-MLV reverse 
transcriptase was added. The reverse transcription reaction continued for 60 minutes at 37 
ºC. Finally, samples were incubated during 5 minutes at 95 ºC to inactivate the reaction 
enzymes and stored at -20 ºC until use. 
 
3.10 Gene cloning 
For gene expression analysis and the evaluation of the efficiency of amplification by qPCR 
primers a different set of specific primers were designed (see Table 3.1) taking advantage 
of available genomic resources (NCBI and ENSEMBL).  
 
Gene Name Access 
Number 
Primer 
Name 
Sequence (5’-3’) Bp 
size 
Col2a1a - ef NM_131292.1 Forward 
Reverse 
TTCACGGACTCTCCTGCTACTTGTG 
GCTCGCCATCTCTCCCTCTTG 
458 
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Alp - ef NM_201007.2 Forward 
Reverse 
TTCCCCACGTCGCCCTCTCT 
ACATGCTTCTCCGCCCACCC 
405 
Runx2 - ef NM_212862.1 Forward 
Reverse 
GCACGGAGAGGGACTGACGG 
AGGGCCACCACCTTAAACGC 
357 
Osx - ef NM_212863.1 Forward 
Reverse 
GTTTCCCAGGACCCTTCGCT 
GCAATCGCAAGAAGACCTCC 
498 
Sox9a - ef NM_131643.1 Forward 
Reverse 
CCAGCGAACACTCAGGC 
TGGTGATGGAGGGAAATGAAG 
483 
Col2a1a - qPCR NM_131292.1 Forward 
Reverse 
CAGGAAGAGTTTGGCGGCTGT 
GACACGGCACGGTTCTGGTT 
81 
Alp - qPCR NM_201007.1 Forward 
Reverse 
TTCCTCTGCGGTGTCAAAGCCAA 
AAGCAGCACTCGGGGTGGCAT 
184 
Mgp - qPCR NM_205640 Forward 
Reverse 
TGTTGTTCTGGCTCTCGGTGCT 
CACCTCCGCACGCCGCTC 
169 
Bgp2 - qPCR 
 
NM_001291889
.1  
Forward 
Reverse 
CCAACTCCGCATCAGACTCCGCATCA 
 
AGCAACACTCCGCTTCAGCAGCACAT  
185 
Runx2 - qPCR NM_212862 Forward 
Reverse 
CTCTCACGCAAACGGAGGACATACG 
TGCATTCGAGTTCACGTCGTTCATCT 
138 
Osx - qPCR NM_212863.1 Forward 
Reverse 
GCTAAGTCCAGGGCAGGCTCAG 
CAATGGCGTGAAATCAGGAGTGTAAC 
115 
Sox9a - qPCR NM_131643.1 Forward 
Reverse 
CGCCCACTCCTCCCACCACC 
GACCGTTCGGCGGGAGGTATTG 
201 
Grp1 - qPCR JQ003911.1 Forward 
Reverse 
CCATTCACTGCTCTCTCAACCACAA 
GGCGGACAAAACAAGCAGACAG 
128 
Rps18 - qPCR NM_173234.1 Forward 
Reverse 
AACACGAACATTGATGGAAGACG 
ATTAGCAAGGACCTGGCTGTATTT 
255 
Β-actin2 - qPCR NM_181601.4 Forward 
Reverse 
GCAGAAGGAGATCACATCCCTGGC 
CATTGCCGTCACCTTCACCGTTC 
322 
 
Table 3.1. Gene names, access numbers (GenBank), primers, primer sequences and expected amplicon 
size (bp) used to perform the evaluation of the efficiency of qPCR primers and the relative gene expression 
quantification in zebrafish larvae exposed to warfarin during embryonic and endotrophic stages. 
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3.10.1 Determination of primers efficiency 
 
To determine the efficiency of the qPCR designed primers (Table 3.1), a PCR reaction was 
done to amplify a fragment of the genes of interest, using zebrafish cDNA as template. In 
the amplification process, two different temperatures of annealing were used (65 and 68 
ºC). For each PCR reaction it was added 1 µL of cDNA in a mix of 2.5 µL of Dream Taq 
buffer 10x, 2.5 µL of dNTPs (10mM), 1.5 µL of specific primers forward and reverse 
(10µM), 0.2 μL of Dream Taq Polymerase and miliQ water to a final volume of 25 μL. 
The PCR were performed under the following conditions: an initial denaturant step at 94 
ºC for 5 minutes, followed by 35 cycles: 94 ºC during 30 seconds, 65 or 68 ºC during 30 
seconds and 72 ºC during 30 seconds. PCR products of the expected size were confirmed 
by a gel electrophoresis. 
 
3.10.2 Purified PCR product’s ligation 
In the ligation procedure the purified PCR products were inserted into pCR® II-TOPO® 
vector. In brief, the ligations on the pCR® II-TOPO® were performed following the 
manufacturer’s instructions. 4 μL of the fresh PCR products were added to 1 μL of pCR® 
II-TOPO® vector and 1 μL of salt solution (6 μL final volume). The reaction was then 
incubated for 5 minutes at RT and then placed in ice. 
 
3.10.3 Transformation of competent bacteria 
The product obtained from the reaction of the previous step was inserted into E. coli - 
DH5α strain. In breaf, 4 μL of the pCR® II-TOPO® ligation reaction was added to a vial 
of E. coli. The tubes were then placed in ice for 30 minutes. Bacteria were incubated 
during 30 seconds at 42 °C (heat shock) to promote the DNA uptake. Under a Bunsen 
burner, 250 μL of a nutritive medium (SOC) was slowly added to the tubes in order to 
activate/potentiate E. coli. Next, bacteria were incubated during 1 hour at 37 °C with 
mechanical agitation (200 rpm). 100 μL of the bacterial suspension was pipetted and 
spread in a pre-warmed (at 37º C) LB agar plate containing ampicillin (100 μL ml-1 LB 
Agar) and X-GAL (40 μL per plate). The plates were then inverted and incubated at 37 °C 
ON. Individual and well defined white colonies (5 colonies per plate) were selected from 
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the plates and grown in 3.5 mL of LB medium with ampicillin (100 μL ml-1 LB) at 37 °C 
under constant mechanical agitation (200 rpm) ON, to promote bacterial colonies growth. 
 
3.10.4 Screening of bacterial colonies by PCR 
In order to confirm the presence of inserts of interest, a polymerase chain reaction (PCR) 
with the M13 primers and other with the specific primers for each gene was performed 
using 2 μL of the bacteria culture as DNA template. The M13 and the specific PCR 
primers will amplify the fragments of DNA that are inserted into the vector allowing us to 
confirm if the colonies are false or true positives. The primers (0.5 μL of 10 µM) were 
added in a mix with Dream Taq buffer 10x (2.5 μL), dNTPs (10 mM; 2.5 μL), Dream Taq 
Polymerase (0.2 μL) and DEPC water (17.8 μL). Finally, PCR products were analyzed by 
electrophoresis in an ethidium bromide (EtBr) agarose gel (1.2 – 2.0 %) in 1x TAE buffer 
and visualized under UV light in a High Performance UV Transluminator (UVP®).  
 
3.10.5 Plasmid DNA extraction, purification and sequencing 
Plasmid DNA extraction was performed manually. Briefly, the bacterial culture was 
centrifuge and the pellet was re-suspended in 100 μL of solution PI, which contains Tris-
HCl (50 mM), ethylenediamine tetraacetic acid (10 mM; EDTA; prevents the activation of 
DNAses) and RNAse (100 µg mL-1; responsible for degradation of RNA). 100 μL of a 
solution PII, which contains sodium dodecyl sulfate (SDS; a detergent that lyses the cells 
wall and denatures cellular proteins) and sodium hydroxide (200 mM; NaOH) was added 
and the mixture was incubated at RT for 5 minutes. After the incubation, 100 μL of 
solution PIII (containing Potassium acetate (3M)) was added to promote bacterial DNA 
and protein precipitation, due to the potassium acetate present in this solution. The mix was 
incubated in ice for 10 minutes and then centrifuged for 5 minutes at 13200 rpm. Plasmid 
DNA was precipitated after adding 2 volumes of 100% EtOH and washing with 2 volumes 
of 70% EtOH and re-suspended in 30 μL DEPC water. Plasmid DNA concentration and 
purity was determined by the absorbance ratios 260/280 and 260/230 nm using a Nanodrop 
1000 spectrophotometer (Thermo Scientific). Finally, samples were sequenced at Centre of 
Marine Sciences (CCMAR) sequencing facility of the with the M13 F and M13 R primers. 
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3.11 Quantitative Real-Time PCR (RT-qPCR) 
To quantify the expression of genes of interest, the cDNA resulting from the RT reaction 
was used as a template for qPCR. qPCR was performed on a Real-Time PCR system  (Bio-
Rad system) using gene-specific forward and reverse primers (Table 3.1). qPCR efficiency 
was close to 100% for all genes. All reactions were performed in triplicates in 96-well 
plates containing 10 ml of SsoFast EvaGreen Supermix (Bio-Rad), 0.5 ml of forward and 
reverse primers (10 µM), 7 ml of molecular biology grade water (Sigma), and 2 ml of a 
1:10 dilution of cDNA template. Amplification parameters were as follows: 95°C for 1 
min, followed by 40 amplification cycles at 95°C for 5 seconds and 65 °C for 10 seconds. 
A final dissociation reaction (melting curve) was performed with the following steps: 95 ºC 
for 15 seconds, 70 ºC for 1 minutes, and 15 seconds at incremental temperatures of 0.5 ºC 
until 95 ºC. A calibrator sample was included in each qPCR plate (Derveaux et al., 2010). 
Relative gene expression was determined according to Pfaffl et al. (2001) using cDNA 
from control larvae groups of both trials as reference samples, and set to one. 
The suitability of 2 housekeeping genes (β-actin2 and rps18) was evaluated using 
NormFinder (Andersen et al. 2004) and BestKeeper (Pfaffl et al. 2004) algorithms. Rps18 
was selected as the best housekeeping gene. 
 
3.12 Statistical analyses  
Results are given as mean ± standard deviation. Differences among all experimental 
groups within each trial were identified by one-way ANOVA and T-test. Correlation 
between variables was evaluated using Pearson Product Moment Correlation test. When 
significant differences were detected in one-way ANOVA, Tukey multiple-comparison test 
was used to determine differences among experimental groups. In all cases, differences 
were considered to be significant when P< 0.05. All statistical analyses were done using 
GraphPad Prism 5.0 (GraphPad Software, Inc.). 
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4. Results 
4.1 Survival rate and larval performance 
 Warfarin exposure during embryonic and endotrophic stages has promoted a wide 
range of effects in zebrafish larvae. Survival of the larvae exposed to increased levels of 
warfarin was clearly affected. Mortality of larvae exposed to gradual concentrations of 
warfarin increased overtime (Fig. 4.1A). However, while exposure during the embryonic 
stage (0-2.5 dpf) promoted a gradual increase in mortality when exposed to the highest 
concentration of warfarin (W125, 125 mg L-1), and significantly higher from 4 dpf 
onwards (32.53 ± 7.09 %; one-way ANOVA, P < 0.05) when compared with the other 
groups (from 13.9 ± 2.55 to19.67 ± 1.70 %); exposure to warfarin during the endotrophic 
stage (2.5-5 dpf) showed quite low mortality until the 7 dpf. From 9 dpf onward, exposure 
to 125 mg L-1 induced a significant increase in mortality (15.65 ± 8.22 %; one-way 
ANOVA, P < 0.05) when compared with Control and lower concentrations (5 and 25 mg 
L-1) of warfarin (from 1.67 ± 2.89 to 3.17 ± 1.4 %). The above mentioned mortality related 
with the exposure (concentration and developmental stage) to warfarin has been translated 
into a statistically different endpoint survival among experimental groups (Fig. 4.1B; one-
way ANOVA, P < 0.05). Exposure to warfarin during the embryonic stage leads to a lower 
survival when treated with 125 mg L-1 (27.72 ± 5.75 %); while during the endotrophic 
stage (same concentration) showed a slighter effect on survival (61.29 ± 13.06 %). 
B A 
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Figure 4.1. Cumulative mortality and endpoint survival rate of zebrafish exposed to increased 
concentrations of warfarin during the embryonic (upper images) and endotrophic stages (bottom images) at 
16 dpf. Cumulative mortality (A) and endpoint survival (B) in zebrafish larvae exposed to increased levels of 
warfarin: 0 (Control), 5 (W5), 25 (W25) and 125 (W125) mg L-1. Different letters at the top of histograms 
denote statistical significant differences among mean values from different experimental groups (one-way 
ANOVA, P < 0.05). 
 
 
Larval performance was also compromised under an induced VK deficiency. 
Standard length at the first sampling point (3 dpf for embryonic and 5 dpf for endotrophic 
stage; Fig. 4.2A) was significantly lower when larvae were exposed to the highest 
concentration of warfarin (2.53 ± 0.01 mm in W125 larvae and ranging from  3.36 ± 0.02 
to 3.31 ± 0.001 mm in Control, W5 and W25 groups, respectively; one-way ANOVA, P < 
0.05). The same effect on standard length has been observed at the end of the experiment 
(16 dpf; Fig. 4.2B). At 16 dpf, larvae exposed to 125 mg L-1 during the embryonic stage 
were still significantly shorter (4.99 ± 0.18 mm) when compared with the larvae from the 
other warfarin treatments (from 8.21 ± 0.09 to 8.18 ± 0.09 mm; one-way ANOVA, P < 
0.05), being those not statistically different to the one of Control larvae (8.19 ± 0.22 mm; 
one-way ANOVA, P > 0.05). However, when larvae were treated with warfarin during the 
endotrophic stage, they also showed a reduced growth in length compared to those not 
treated (Control), although the effect was slighter than in larvae exposed to warfarin during 
embryonic stage. In this case, W125 larvae showed the lowest standard length and 
significantly different to the larvae from the remaining experimental groups, showing W5 
and W25 larvae intermediate values and also significantly different to those from Control 
larvae (7.43 ± 0.09 mm in Control group versus 6.99 ± 0.09, 7.10 ± 0.08, and 6.50 ± 0.15 
mm in W5, W25 and W125, respectively; one-way ANOVA, P < 0.05). 
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Figure 4.2. Standard length of larvae exposed to increased concentrations of warfarin during the 
embryonic (upper images) and endotrophic stages (bottom images) at different sampling points (3 and 16 dpf 
for embryonic stage treatment; 5 and 16 dpf for endotrophic stage treatment). Growth in standard length at 3 
and 5 dpf  (A) and growth in standard length at 16 dpf (B) in zebrafish larvae exposed to increased levels of 
warfarin: 0 (Control), 5 (W5), 25 (W25) and 125 (W125) mg L-1. Different letters at the top of histograms 
denote statistical significant differences among mean values from different experimental groups (one-way 
ANOVA, P < 0.05). 
 
 
In addition to the effects on survival and standard length, larvae exposed to 
warfarin also showed hemorrhagic events. At the first sampling point larvae exposed to 25 
and 125 mg L-1 showed hemorrhages in abdominal region as well in the head (Fig. 4.3); 
however only the W125 group showed a significantly higher percentage with hemorrhages 
(60.83 ± 5.57 %; one-way ANOVA, P > 0.05). Similarly, although with a lower incidence 
(8.33 ± 0.01 %) comparing to the larvae treated during embryonic development, this 
feature was also seen in zebrafish exposed to highest warfarin concentration during the 
endotrophic stage. Furthermore, as occurred in embryonic stage, incidence of hemorrhages 
was not significantly different between untreated and larvae exposed to 5 and 25 mg L-1 of 
warfarin.  
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Figure 4.3. Percentage of larvae showing hemorrhages when exposed to increased concentrations of 
warfarin during the embryonic (left) and endotrophic stages (right) at 3 and 5 dpf, respectively (A). Larva 
treated with 5 mg L-1 with no hemorrhage versus larva treated with 25 mg L-1 showing cranial hemorrhage at 
3dpf (B); asterisk indicates the local of hemorrhage. Levels of warfarin: 0 (Control), 5 (W5), 25 (W25) and 
125 (W125) mg L_1. Different letters at the top of histograms denote statistical significant differences among 
mean values from different experimental groups (one-way ANOVA, P < 0.05). Scale bar = 500 µm. 
 
 
 
Yolk sac development was also compromised by warfarin exposure. Exposure to 
highest warfarin concentration during embryonic as well as during endotrophic 
development induced an opaque appearance of the yolk sac (Fig. 4.4). 54.44 ± 8.75 and 
25.0 ± 11.79 % of the W125 larvae from embryonic and endotrophic development trials 
(respectively), showed this particular phenotype that has not been observed in Control, W5 
and W25 treated larvae at 3 and 5 dpf sampling points. 
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Figure 4.4. Percentage of larvae at 3 and 5 dph showing an opaque yolk sac when exposed to increased 
concentrations of warfarin during the embryonic (left image) and endotrophic stages (right image), 
respectively (A). Larva treated with 5 mg L-1  with no opaque yolk sac versus larva treated with 125 mg L-1 
showing an opaque yolk sac at 3dpf (B); asterisk indicates  yolk sac affected. Levels of warfarin: 0 (Control), 
5 (W5), 25 (W25) and 125 (W125) mg L-1. Different letters at the top of histograms denote statistical 
significant differences among mean values from different experimental groups (one-way ANOVA, P < 0.05). 
Scale bar = 500 µm. 
 
 
Warfarin exposure also promoted the development of pericardial inflammation in 
zebrafish larvae (Fig. 4.5), with this effect being significant only in W125 exposed larvae 
and more pronounced when zebrafish were exposed to warfarin during embryonic rather 
than endotrophic (65.56 ± 15.48 and 11.11 ± 3.93 %, respectively; one-way ANOVA, P > 
0.05) development. In fact, while pericardial inflammation was also observed in W5 and 
W25, larvae from the embryonic exposure, although in lower percentages (ranging 4.44 ± 
3.14 to 8.89 ± 3.14 %), it was not found in W5 and W25 larvae from endotrophic exposure. 
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A 
Zebrafish as a model of warfarin embryopathy        Chapter 4 
32 
 
 
 
Figure 4.5. Percentage of larvae showing pericardial inflammation when exposed to increased 
concentrations of warfarin during the embryonic (left) and endotrophic stages (right) at 3 and 5 dpf, 
respectively (A). Larva treated with 0 mg L-1  with no pericardiac inflammation versus larva treated with 125 
mg L-1 showing cardiac inflammation at 3dpf (B); asterisk indicates the pericardiac edema. Levels of 
warfarin: 0 (Control), 5 (W5), 25 (W25) and 125 (W125) mg L-1. Different letters at the top of histograms 
denote statistical significant differences among mean values from different experimental groups (one-way 
ANOVA, P < 0.05). Scale bar = 500 µm. 
 
The swimbladder development was also evaluated in zebrafish larvae. In this sense, 
zebrafish exposed to highest concentration of warfarin did not show a completely 
developed swimbladder (Fig. 4.6). At 16 dpf, only a little (12.73 ± 9.03 %; one-way 
ANOVA, P > 0.05) and a considerable percentage (46.50 ± 8.45 %; one-way ANOVA, P > 
0.05) of larvae showed a fully developed swimbladder when exposed to 125 mg L-1 during 
the embryonic and endotrophic development, respectively. On the contrary, Control, W5 
and W25 groups from both trials presented a high percentage of larvae with a normal 
swimbladder (with two lobules clearly differentiated). 
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Figure 4.6. Percentage of larvae with the swimbladder fully developed when exposed to increased 
concentrations of warfarin during the embryonic (left image) and endotrophic stages (right image) at 16 dpf 
(A). Larva control with two swimbladder lobules clearly differentiated versus larva treated with 125 mg L-1 
with only one swimbladder lobule formed (B); asterisk indicates the local of swimbladder in larvae. Levels of 
warfarin: 0 (Control), 5 (W5), 25 (W25) and 125 (W125) mg L-1. Different letters at the top of histograms 
denote statistical significant differences among mean values from different experimental groups (one-way 
ANOVA, P < 0.05). Scale bar = 500 µm. 
 
 
 
4.2 Zebrafish skeletogenesis 
Skeletal development was also analyzed in larvae exposed to warfarin during embryonic 
and endotrophic stages, and particularly regarding the mineralization status of cranial and 
axial skeleton, and the morphometry of several cranial structures.  
4.2.1 Cranial structures 
The mineralization degree was analyzed in several structures of the cranium, where are 
included the basioccipital (bop), operculum, cleithrum, ceratohyal arches and 
parasphenoid. Regarding the morphometry, the meckel’s cartilage, ceratohyal arches, the 
1st ceratobranchial arch and the ethmoid plate were analyzed.  
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 The mineralization degree was affected by warfarin exposure. While the bop was 
clearly visible in Control larvae, as it is showed fully mineralized; zebrafish exposed to 
increasing concentrations of warfarin during embryonic and endotrophic stages exhibited a 
less mineralized bop at 5 and 7 dpf, respectively (Fig. 4.7). When zebrafish were exposed 
to warfarin during the embryonic stage, the effect was more severe and none of the larvae 
treated with 125 mg L-1 had a mineralized bop at 5 dpf. Furthermore, this effect was still 
persistent at 7 dpf as a high percentage of larvae (72.22 ± 20.78 %; one-way ANOVA, P > 
0.05) from W125 group showed a non-mineralized bop. Also, larvae from W25 group 
showed mineralization of bop affected at 5 dpf, with a considerable percentage (6.67 ± 
9.43 %) presenting the structure non-mineralized and (60.00 ± 16.33 %) having a less 
mineralized bop. At 7 dpf, the mineralization degree between Control and the lower 
concentrations of warfarin was similar. When zebrafish were exposed to warfarin during 
endotrophic stage the effect was less evident; only a low percentage of larvae (22.98 ± 4.56 
%) from W125 group showed no mineralization at 5 dpf, while these larvae presented a 
mineralization degree similar to the control at 7 dpf. 
 
Figure 4.7. Percentage of zebrafish showing different mineralization degrees of the basioccipital (bop) 
when exposed to increased concentrations of warfarin during the embryonic (upper images) and endotrophic 
stages (bottom images). Percentage of larvae with different mineralization degree of bop at 5 (A) and 7 dpf 
(B) in zebrafish larvae exposed to increased levels of warfarin: 0 (Control), 5 (W5), 25 (W25) and 125 
(W125) mg L-1. Representative images of mineralized, less mineralized and not mineralized bop at 5 dpf (C). 
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Asterisks highlights bop in zebrafish larvae. Different colors in bars represent mineralization degree: blue, 
not mineralized; red, slightly mineralized; and green, mineralized. Scale bar = 100 µm. 
 
 
 
Regarding to operculum, as occurred with the bop, the process of mineralization of 
this structure was affected, since a visible decrease in its mineralization on larvae exposed 
to the highest concentrations of warfarin in embryonic and endotrophic stages was found 
(Fig. 4.8). Zebrafish exposed to 125 mg L-1 of warfarin during the embryonic stage were 
the most affected group, showing no mineralization at 5 dpf. Larvae from W25 group also 
showed the operculum affected, since in a low percentage it was not (6.67 ± 9.43 %) or 
slightly mineralized (13.33 ± 18.86 %). At 7 dpf the effect was slighter, however all larvae 
from W125 group still presented the operculum less mineralized. When zebrafish were 
exposed to warfarin during endotrophic stage the effect was similar to the registered in 
embryonic one. Here, a significant percentage of larvae from W125 group (54.29 ± 3.40 
%; one-way ANOVA, P > 0.05) showed the operculum not mineralized at 5 dpf; in 
contrast, the mineralization degree of larvae from Control and the lower concentrations of 
warfarin were similar. At 7 dpf, the effect was less visible, however larvae from W125 
group still showing the operculum not full mineralized (69.44 ± 3.93 %; one-way 
ANOVA, P > 0.05). 
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Figure 4.8. Percentage of zebrafish showing different mineralization degree of operculum when exposed 
to increased concentrations of warfarin during the embryonic (upper image) and endotrophic stages (bottom 
image). Percentage of larvae with different mineralization degree of operculum at 5 (A) and 7 dpf (B) in 
zebrafish larvae exposed to increased levels of warfarin: 0 (Control), 5 (W5), 25 (W25) and 125 (W125) mg 
L-1. Representative images of mineralized and not mineralized operculum at 5 dpf (C). Cardinals highlights 
operculum in zebrafish larvae. Different colors in bars represent mineralization degree: blue, not mineralized; 
red, slightly mineralized; and green, mineralized. Scale bar = 100 µm. 
 
The effect promoted by the exposition to warfarin in the cleithrum was also clear 
(Fig. 4.9). Larvae exposed to 125 mg L-1 of warfarin during the embryonic stage presented 
the most severe effect, and a significant percentage of larvae (88.89 ± 15.71 %; one-way 
ANOVA, P > 0.05) had the cleithrum not mineralized at 5 dpf. Larvae exposed to 25 mg L-
1 also showed an effect, however less accentuated. A low percentage had the cleithrum not 
mineralized (6.67 ± 9.43 %) and a considerable percentage showed it slightly mineralized 
(33.33 ± 18.86 %).  At 7 dpf the effect was smaller; the W125 group still showed the most 
severe effect, and all larvae had the cleithrum slightly mineralized; the mineralization 
degree between Control and the lower concentrations of warfarin was similar. When larvae 
were exposed to warfarin during endotrophic stage the effect was similar to the one seen in 
larvae exposed to warfarin during the embryonic stage; larvae treated with 125 mg L-1 
were the most affected group, where a considerable percentage of larvae (45.20 ± 13.13 %; 
one-way ANOVA, P > 0.05) showing no mineralization in cleithrum at 5 dpf. At 7 dpf, the 
effect was less accentuated and all larvae showed mineralization in the cleithrum; in W125 
group, the most affected group, a high percentage of larvae (69.44 ± 3.93 %; one-way 
ANOVA, P > 0.05) showed the cleithrum slightly mineralized, while a low percentage 
(30.56 ± 3.93 %; one-way ANOVA, P > 0.05) showed it fully mineralized; the lower 
concentrations of warfarin showed a similar mineralization degree when compared with 
Control. 
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Figure 4.9. Percentage of zebrafish showing different mineralization degree of cleithrum when exposed to 
increased concentrations of warfarin during the embryonic (upper image) and endotrophic stages (bottom 
image). Percentage of larvae with different mineralization degree of cleithrum in zebrafish larvae at 5 dpf (A) 
and 7 dpf (B) exposed to increased levels of warfarin: 0 (Control), 5 (W5), 25 (W25) and 125 (W125) mg L-
1. Representative images of mineralized, less mineralized and not mineralized cleithrum at 5 dpf (C). 
Asterisks highlights cleithrum in zebrafish larvae. Different colors in bars represent mineralization degree: 
blue, not mineralized; red, slightly mineralized; and green, mineralized. Scale bar = 100 µm. 
 
 
Mineralization degree of ceratohyal arches (Fig. 4.10) in larvae exposed to 
increasing concentrations of warfarin during embryonic and endotrophic stages was similar 
when compared to that of Control larvae at 5 dpf. In contrast, at 7 dpf, while larvae treated 
with 125 mg L-1 during embryonic stage showed no mineralization in ceratohyal, a 
significant percentage of larvae from Control and the lower concentrations of warfarin 
showed the structure slightly mineralized (80.0 ± 16.33, Ctr; 68.89 ± 24.55, W5 and 80.0 ± 
0.0 %, W25). In contrast to this, when larvae were treated during the endotrophic stage, 
although a greater percentage of larvae from W125 group (94.44 ± 7.86 %) showed the 
ceratohyal not mineralized, the mineralization degree was similar to the registered in the 
other experimental groups. 
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Figure 4.10. Percentage of zebrafish showing different mineralization degree of ceratohyal arches when 
exposed to increased concentrations of warfarin during the embryonic (upper image) and endotrophic stages 
(bottom image). Percentage of larvae with different mineralization degree of ceratohyal arches in zebrafish 
larvae at 5 dpf (A) and 7 dpf (B) exposed to increased levels of warfarin: 0 (Control), 5 (W5), 25 (W25) and 
125 (W125) mg L-1. Representative images of less mineralized and not mineralized ceratohyal arches at 5 dpf 
(C). Cardinals highlights ceratohyal arches in zebrafish larvae. Different colors in bars represent 
mineralization degree: blue, not mineralized; red, slightly mineralized. Scale bar = 100 µm. 
 
 
 
The last structure analyzed in the cranium was the parasphenoid (Fig. 4.11). Here, 
the effect was similar to the one found in the previous analyzed structures. A deficit of 
mineralization in larvae exposed to the highest concentrations of warfarin (25 and 125 mg 
L-1) was found when zebrafish were treated during embryonic and endotrophic stages at 5 
and 7 dpf. When zebrafish were exposed to warfarin during the first stage, the effect was 
more severe in those treated with 125 mg L-1, since no mineralization was detected at 5 
dpf. The effect was smaller in larvae treated with 25 mg L-1 and a considerable percentage 
(40.0 ± 16.33 %) had the parasphenoid somewhat mineralized. At 7 dpf the effect was 
similar. Most of the larvae treated with 125 mg L-1 (72.22 ± 20.79 %; one-way ANOVA, P 
> 0.05) showed no mineralization in the parasphenoid, while similar mineralization degree 
was found between Control and the lower concentrations of warfarin. When zebrafish were 
exposed to warfarin during the endotrophic stage, the effect was similar to the one 
observed in the embryonic trial. Larvae treated with 125 mg L-1 were the most affected and 
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a significant percentage of larvae (62.63 ± 8.89 %; one-way ANOVA, P > 0.05) showed 
no mineralization at 5 dpf. Larvae treated 25 mg L-1 was also affected, however, in a 
slighter way since a greater percentage of larvae (60.0 ± 28.28 %) had the parasphenoid 
fully mineralized, and a considerable percentage (26.67 ± 24.94 %) had the parasphenoid 
at least slightly mineralized. At 7 dpf, the effect was less accentuated and all larvae have 
presented this structure mineralized. Nevertheless, W125 group was still the most affected, 
with a high percentage of larvae (75.0 ± 20.41 %; one-way ANOVA, P > 0.05) showing 
this structure less mineralized. In contrast, the degree of mineralization of Control and the 
lower concentrations of warfarin groups was similar. 
 
Figure 4.11.  Percentage of zebrafish showing different mineralization degree of parasphenoid when 
exposed to increased concentrations of warfarin during the embryonic (upper image) and endotrophic stages 
(bottom image). Percentage of larvae with different mineralization degree of parasphenoid in zebrafish larvae 
at 5 dpf (A) and 7 dpf (B) exposed to increased levels of warfarin: 0 (Control), 5 (W5), 25 (W25) and 125 
(W125) mg L-1. Representative images of mineralized, less mineralized and not mineralized parasphenoid at 
5 dpf (C). Asterisks highlights parasphenoid in zebrafish larvae. Different colors in bars represent 
mineralization degree: blue, not mineralized; red, slightly mineralized; and green, mineralized. Scale bar = 
100 µm. 
 
 
Besides the clear effect in mineralization, warfarin exposure has also compromised 
the morphometry of the endochondral structures present in the cranial region. One of these 
structures was the meckel’s cartilage (Fig. 4.12). When larvae were treated with warfarin 
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during the embryonic stage, W125 group showed a significantly shorter structure at both 5 
dpf and at 7 dpf (133.75 ± 5.42 and 173.48 ± 6.30 µm, respectively; one-way ANOVA, P 
< 0.05) when compared with the other treatments (ranging from 206.79 ± 5.80 to 197.69 ± 
0.89 µm at 5 dpf, and 226.59 ± 12.44 to 209.58 ± 4.63 µm at 7 dpf). Similarly, larvae 
exposed to 125 mg L-1 during the endotrophic stage showed a significantly shorter structure 
at 5 dpf (157.54 ± 20.27 µm; one-way ANOVA, P < 0.05) when compared with the other 
treatments (ranging from 196.33 ± 8.02  to 191.45 ± 2.19 µm).  At 7 dpf, larvae from 
W125 still showed a significantly shorter meckel’s cartilage but only when compared with 
Control larvae (187.35 ± 2.13 versus 204.99 ± 9.09 µm, respectively; one-way ANOVA, P 
< 0.05), with larvae from W5 and W25 groups showing intermediate values (from 200.07 
± 6.97 to 199.6 ± 4.11 µm). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Mean length of meckel’s cartilage in zebrafish exposed to increased concentrations of 
warfarin during the embryonic (upper image) and endotrophic stages (bottom image), respectively. Mean 
length of meckel’s cartilage in zebrafish larvae at 5 dpf (A) and 7 dpf (B) exposed to increased levels of 
warfarin: 0 (Control), 5 (W5), 25 (W25) and 125 (W125) mg L-1. Different letters at the top of histograms 
denote statistical significant differences among mean values from different experimental groups (one-way 
ANOVA, P < 0.05). 
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The ceratohyal length (Fig. 4.13) was also affected when zebrafish were exposed to 
increasing concentrations of warfarin at 5 and 7 dpf. As occurred in meckel’s cartilage, the 
most severe effect was seen in larvae exposed to 125 mg L-1. When zebrafish were exposed 
to this concentration during the embryonic stage a significant shorter structure was seen at 
5 (172.77 ± 5.54 µm; one-way ANOVA, P > 0.05) and 7 dpf (207.16 ± 7.95 µm; one-way 
ANOVA, P > 0.05) comparing to the larvae from the other treatments (ranging from 
253.06 ± 7.57 to 246.42 ± 3.08 µm at 5 dpf, and from 272.12 ± 4.12 to 256.34 ± 3.13 µm 
at 7 dpf). Furthermore, at 7 dpf, larvae exposed to 25 mg L-1 (256.34 ± 3.13 µm) presented 
an intermediate phenotype. A similar effect was found when larvae were exposed to the 
highest concentration during the endotrophic stage, since the ceratohyal arch was found 
significantly shorter at 5 (209.6 ± 15.79 µm; one-way ANOVA, P > 0.05) and 7 dpf 
(236.05 ± 6.55 µm; one-way ANOVA, P > 0.05) when compared to Control and the lower 
concentrations of warfarin (ranging from 243.13 ± 1.88 to 231.79 ± 2.85 µm at 5 dpf, and 
from 256.41 ± 5.76 to 243.53 ± 5.38 µm at 7 dpf). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Mean length of ceratohyal arches in larvae exposed to increased concentrations of warfarin 
during the embryonic (upper image) and endotrophic stages (bottom image), respectively. Mean length of 
ceratohyal arches in zebrafish larvae at 5 dpf (A) and 7 dpf (B) exposed to increased levels of warfarin: 0 
(Control), 5 (W5), 25 (W25) and 125 (W125) mg L-1. Different letters at the top of histograms denote 
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statistical significant differences among mean values from different experimental groups (one-way ANOVA, 
P < 0.05). 
 
The first ceratobranchial arch was also analyzed (Fig. 4.14). Larvae exposed to the 
highest concentration of warfarin showed the most severe effect at 5 and 7 dpf. When 
larvae were exposed 125 mg L-1 during the embryonic stage, a significant shorter structure 
was found (126.89 ± 10.37 µm; one-way ANOVA, P < 0.05) when compared with the 
larvae from the other treatments at 5 dpf (ranging from 226.93 ± 1.94 to 211.45 ± 5.69 µm) 
and similarly at 7 dpf. When larvae were exposed to increased levels of warfarin during the 
endotrophic stage, only larvae from W125 group showed a significant shorter first 
ceratobranchial at 5 and 7 dpf (168.34 ± 20.48 and 194.23 ± 9.33 µm, respectively; one-
way ANOVA, P < 0.05) when compared with Control larvae. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. Mean length of the 1st ceratobranchial arch in larvae exposed to increased concentrations of 
warfarin during the embryonic (upper image) and endotrophic stages (bottom image), respectively. Mean 
length of the 1st ceratobranchial arch in zebrafish larvae at 5 dpf (A) and 7 dpf (B) exposed to increased 
levels of warfarin: 0 (Control), 5 (W5), 25 (W25) and 125 (W125) mg L-1. Different letters at the top of 
histograms denote statistical significant differences among mean values from different experimental groups 
(one-way ANOVA, P < 0.05). 
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The width of the ethmoid plate (Fig. 4.15) was found affected. Larvae exposed to 
warfarin during the embryonic development, in particular to 125 mg L-1 at 5 dpf and at 7 
dpf had a significantly narrower structure (117.51 ± 7.97 µm; one-way ANOVA, P > 
0.05), comparing with the other experimental groups (range from 199.24 ± 1.80 to 189.64 
± 4.34 µm). When treated during the endotrophic stage, larvae from W125 group showed a 
significant reduction in width (162.02 ± 14.74 µm; one-way ANOVA, P > 0.05) when 
compared with the lower concentrations of warfarin, being the effect visible at 5 dpf.  At 7 
dpf, the effect found was less evident; however, larvae exposed to 125 mg L-1 still had a 
significantly narrower structure (180.02 ± 9.51 µm) compared to that found in Control 
larvae. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15. Mean width of the ethmoid plate in larvae exposed to increased concentrations of warfarin 
during the embryonic (upper image) and endotrophic stages (bottom image), respectively. Mean width of the 
ethmoid plate in zebrafish larvae at 5 dpf (A) and 7 dpf (B) exposed to increased levels of warfarin: 0 
(Control), 5 (W5), 25 (W25) and 125 (W125) mg L-1. Different letters at the top of histograms denote 
statistical significant differences among mean values from different experimental groups (one-way ANOVA, 
P < 0.05). 
 
 
Regarding to the length of the ethmoid plate (Fig. 4.16), larvae exposed to 125 mg 
L-1 were the most affected, being the effect more severe when they were exposed to 
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warfarin during the embryonic stage. At 5 dpf, larvae treated during this stage showed an 
ethmoid plate significantly shorter (129.36 ± 3.87 µm; one-way ANOVA, P > 0.05) when 
compared with the other experimental groups (ranging from 253.04 ± 11.96 to 224.74 ± 
8.82 µm). At 7 dpf, a similar effected was found, with larvae exposed to 125 mg L-1 having 
an ethmoid plate still significantly shorter (188.64 ± 27.94 µm; one-way ANOVA, P > 
0.05). Furthermore, larvae treated 25 mg L-1 showed an intermediate phenotype between 
Control and W125 larvae. Exposure to warfarin during the endotrophic stage promoted 
similar effect in larvae, although less accentuated. At 5 dpf, W125 group was the most 
affected, with larvae showing a significant shorter structure (178.15 ± 26.68 µm; one-way 
ANOVA, P > 0.05) compared to that of the Control larvae. At 7 dpf, a similar effect was 
found with W125 larvae showing a significantly shorter structure (204.43 ± 5.23 µm; one-
way ANOVA, P > 0.05) compared to the other groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16. Mean length of the ethmoid plate in larvae exposed to increased concentrations of warfarin 
during the embryonic (upper image) and endotrophic stages (bottom image), respectively. Mean length of the 
ethmoid plate in zebrafish larvae at 5 dpf (A) and 7 dpf (B) exposed to increased levels of warfarin: 0 
(Control), 5 (W5), 25 (W25) and 125 (W125) mg L-1. Different letters at the top of histograms denote 
statistical significant differences among mean values from different experimental groups (one-way ANOVA, 
P < 0.05). 
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Unlike the previous parameters, only larvae treated with warfarin during the 
embryonic stage and with the highest concentration were significantly affected regarding 
the angle formed by the ethmoid plate (Fig. 4.17). The larvae analyzed showed a larger 
angle at 5 dpf (80.70 ± 13.96 °; one-way ANOVA, P > 0.05) and 7 dpf (65.50 ± 5.79 °; 
one-way ANOVA, P > 0.05) when compared to the rest of the treatments at 5 dpf (48.81 ± 
3.93 °, Ctr; 49.77 ±1.81 , W5; 51.69 ± 1.43 °, W25); and at 7 dpf (49.52 ± 3.99 °, Ctr; 
50.69 ± 4.47, W5; 51.19  ± 0.99 °, W25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 Mean angle of the ethmoid plate in larvae exposed to increased concentrations of warfarin 
during the embryonic (upper image) and endotrophic stages (bottom image), respectively. Mean angle of the 
ethmoid plate in zebrafish larvae at 5 dpf (A) and 7 dpf (B) exposed to increased levels of warfarin: 0 
(Control), 5 (W5), 25 (W25) and 125 (W125) mg L-1. Different letters at the top of histograms denote 
statistical significant differences among mean values from different experimental groups (one-way ANOVA, 
P < 0.05). 
 
 
4.2.2 Axial skeleton 
As in the cranial region, mineralization in axial skeleton (Fig. 4.18) was also found 
to be affected by exposure to warfarin at the end of the experiment (16 dpf). However, a 
clear decrease of mineralization was only visible in larvae exposed to 125 mg L-1. In this 
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sense, when zebrafish were treated during the embryonic stage, the most affected one, a 
significantly lower percentage of larvae had mineralized the vertebrae. In contrast, 
although larvae treated during the endotrophic stage were also affected, most of them 
exposed to the highest concentration showed a normal mineralization pattern in most of the 
vertebra; only a low percentage of larvae showed a normally mineralization on the last 
vertebrae.  
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Figure 4.18. Percentage of zebrafish showing different mineralization of vertebrae when exposed to 
increased concentrations of warfarin. Percentage of larvae with vertebrae mineralized in zebrafish larvae at 
16 dpf exposed to increased levels of warfarin during the embryonic (A) and endotrophic stages (B): 0 
(Control), 5 (W5), 25 (W25) and 125 (W125) mg L-1.  Representative images of mineralized and non-
mineralized axial skeleton at 16 dpf (C). Scale bar = 1mm. 
 
 
 
4.3 Gene expression 
To better understand the mechanisms that regulate skeletal formation in zebrafish under 
exposure to warfarin during the embryonic and endotrophic stages, expression levels of 
genes related to skeletogenesis (sox9a, runx2, osx, col2a1, grp1, alp, mgp and bgp) were 
determined by qPCR in larvae from Control, W25 and W125 at 3 dpf in embryos exposed 
to warfarin during the embryonic stage, at 5 dpf in larvae exposed to warfarin during the 
endotrophic stage and in Control and W125 larvae at 16 days when they were exposed to 
warfarin during the endotrophic stage. 
 In larvae exposed to warfarin during the embryonic stage only sox9a was affected 
regarding to the transcriptional factors controlling skeletogenesis at 3 dpf; being only 
significantly down regulated in larvae from W125 group (t-test, P < 0.05; Fig. 4.19). While 
the expression of alkaline phosphatase (alp) was not found to be altered in larvae exposed 
to increased levels of warfarin; two genes encoding for extracellular matrix proteins 
col2a1a and grp1 were found significantly down-regulated. In particular, while col2a1a 
was only significantly down-regulated in larvae from W125 group with respect to larvae 
from Control group, grp1 was found to be down-regulated in larvae from W25 and W125 
groups (one-way ANOVA, P < 0.05). 
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Figure 4.19. Relative expression of sex determining region Y-box 9a, runt-related transcription factor 2,  
osxterix, collagen type 2, gla-rich protein 1 and alkaline phosphatase genes in zebrafish at 3 dpf upon 
exposure to warfarin during embryonic stage: 0 (Ctr) and 25 (W25) and 125 (W125) mg L-1. Transcript levels 
were determined by qPCR from 3 biological replicates (3 technical replicates per biological replicate) and 
normalized using Rps18 housekeeping gene. An asterisk denotes statistical difference among two groups by 
t-test, while different letters statistical difference among experimental groups by one-way ANOVA (P < 
0.05). Relative gene expression was determined using cDNA from control larvae groups as reference 
samples, and set to one. Sox9a, sex determining region Y-box 9a; runx2, runt-related transcription factor 2; 
osx, osterix; col2a1a, collagen type 2; grp1, gla-rich protein 1; alp, alkaline phosphatase. 
 
 
At 5 dpf (Fig. 4.20), osx expression was significantly decreased in larvae exposed 
to the highest concentration of warfarin (W125) compared to that of larvae from the 
Control group (one-way ANOVA, P < 0.05). Although col2a1a gene expression was not 
statistically different among experimental groups, a negative correlation between warfarin 
concentration and its level of expression (Pearson product-moment correlation; P = 0.034; 
R2 = 0.555) was found. Also, grp1 and alp were significantly affected, being down-
regulated in W125 larvae when compared to Control larvae (t-test and one-way ANOVA, 
respectively; P < 0.05). 
 
Figure 4.20. Relative expression of sex determining region Y-box 9a, runt-related transcription factor 2, 
osxterix, collagen type 2 alpha 1a, gla-rich protein 1and alkaline phosphatase genes in zebrafish larvae at 5 
dpf upon exposure to warfarin during endotrophic stage: 0 (Ctr) and 25 (W25) and 125 (W125) mg L-1. 
Transcript levels were determined by qPCR from 3 biological replicates (3 technical replicates per biological 
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replicate) and normalized using Rps18 housekeeping gene. An asterisk denotes statistical difference among 
two groups by t-test while different letters statistical difference among experimental groups by one-way 
ANOVA (P < 0.05). Relative gene expression was determined using cDNA from control larvae groups as 
reference samples, and set to one. Sox9a, sex determining region Y-box 9a; runx2, runt-related transcription 
factor 2; osx, osterix; col2a1a, collagen type 2 alpha 1a; grp1, gla-rich protein 1; alp, alkaline phosphatase. 
 
 
 
Finally, since not enough larvae from W125 group in the embryonic exposure trial 
survived until 16 dpf, gene expression was only evaluated in larvae from Control and 
W125 groups in the endotrophic exposure at the end of the trial (Fig. 4.21). In this case, 
runx2 and osx gene expression was higher in W125 larvae compared to that of Control 
group larvae (one-way ANOVA, P < 0.05). In contrast, col2a1a, mgp, bgp and alp were 
not significantly affected by warfarin exposure (t-test, P > 0.05). 
 
 
Figure 4.21. Relative expression of runt-related transcription factor 2, osxterix, collagen type 2, matrix 
gla protein, bone gla protein and alkaline phosphatase in zebrafish larvae at 16 dpf upon exposure to 
warfarin during larval stage: 0 (Ctr) and 125 (W125) mg L-1. Transcript levels were determined by qPCR 
from 3 biological replicates (3 technical replicates per biological replicate) and normalized using Rps18 
housekeeping gene. An asterisk over the expression level of W125 group denotes statistical difference with 
the expression level of Control group (t-test; P < 0.05). Relative gene expression was determined using 
cDNA from control larvae groups as reference samples, and set to one. Runx2, runt-related transcription 
factor 2; osx, osterix; col2a1a, collagen type 2 alpha 1a; mgp, matrix gla protein; bgp2, bone gla protein 2; 
alp, alkaline phosphatase.  
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5. Discussion 
 
It is known that warfarin can prevent VK action since it is responsible for the blockage of 
its recycling; and thus the blood coagulation by limiting the γ-carboxylation of coagulation 
factors (Stafford, 2005; Oldenburg et al., 2008). However, some undesired effect can arise 
when warfarin therapies are applied in humans. An example is the syndrome named 
Warfarin Embryopathy (WE), which comprises a wide range of manifestations like 
dysmorphology in neonate with chondrodysplasia punctate (nasal hypoplasia and stippling 
of epiphyses) and spine abnormalities (Menger et al., 1997; Sathienkijkanchai and Wasant, 
2005; Mehndiratta et al., 2010) when pregnant women are under warfarin therapy.Some 
works have reported the teratogenic effects of warfarin exposure, like bleeding (Fernandez 
et al., 2014) and skeletal disorders (Weigt et al., 2012; Fernandez et al., 2014) using 
zebrafish as a model; however the main underlying pathways by which warfarin exposure 
during early development induce abnormal skeletogenesis are not known. 
In this work we analyzed the effects of warfarin exposure during the early 
development of zebrafish, and new insights on the specific underlying mechanisms of 
abnormal skeletogenesis are provided.  
 
 
Zebrafish larval performance under warfarin exposure  
Warfarin exposure during the early development of zebrafish (embryonic and endotrophic 
stages) showed a set of negative effects on larval performance including growth 
retardation, hemorrhages, swimbladder underdevelopment, pericardiac inflammation, 
abnormal appearance of yolk sac,  skeletogenesis disruption and increased mortality.  
A major effect of warfarin exposure has been largely described in the literature: the 
blockage of VK recycling, through warfarin binding to vitamin K epoxide reductases 
(Vkor), which is needed as a cofactor for γ-glutamyl carboxylase (Ggcx) in order to 
perform the γ-carboxylation of VK dependent proteins (VKDPs; Stafford, 2005; 
Oldenburg et al., 2008) but also as a ligand for Pxr (Tabb et al., 2003). The γ-carboxylation 
is required to provide calcium binding properties to VKDPs (Stafford, 2005; Oldenburg et 
al., 2008) and thus, allowing them to control Ca2+ homeostais. Pxr plays important roles 
related to detoxification of the organism (drug metabolism), bone homeostasis, but also 
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regulating metabolic pathways for the elimination of cholesterol and regulating the glucose 
metabolism (Timsit and Negishi, 2007).  
Growth retardation was found in larvae exposed to highest concentrations of 
warfarin, in particular to 125 mg L-1 exposure during embryonic as well as endotrophic 
stages. This feature is reported in literature (Menger et al., 1997; Hou, 2004), being present 
in infants exposed to warfarin during pregnancy (WE). Low standard length could be in a 
first moment explained by the effect promoted by warfarin in endochondral bone 
formation. Further, it also could be related in a second moment to malnutrition due to 
malformations in the mouth but also problems in locomotion, implying a lower success in 
catching live prey. As a consequence, this lower growth in larvae might affect survival, 
and explaining at least in part the higher mortality recorded in these larvae. 
In larvae exposed to high concentrations of warfarin, hemorrhagic events were 
observed in brain as well as in abdominal region. The bleeding disorder have been already 
reported as an output of warfarin exposure in early development (Fernandez et al., 2014) 
and could be related to several factors; (i) decrease in γ-carboxylation of clotting factors, 
which are responsible for blood coagulation (Stafford, 2005; Oldenburg et al., 2008); (ii) 
ectopic calcification of soft tissues, in particular vascular tissues, due to the the 
undercarboxylated state of particular VKDPs like the Mgp (Schurgers et al., 2013). Mgp is 
synthesized by the vascular smooth muscle cells and is a major inhibitor of arterial 
calcification. Thus, its undercarboxylation promotes a reduction in the elasticity of the 
vessels (Luo et al., 1997). Bleeding disorders are one feature of WE in infants (Hou, 2004; 
Wainwright and Beighton, 2010; Mehndiratta et al., 2010). Further, Johnson et al. (2006) 
showed in Rambouillet sheep that defective γ-glutamyl carboxylase activity caused 
bleeding disorder in lambs, while brain bleeding disorder was observed by Spohn et al. 
(2009) in Vkorc1 knockout mice. Also Zhu et al. (2007) reported fatal hemorrhages in 
mice lacking γ -glutamyl carboxylase. More recently, Azuma et al. (2014) showed that γ-
glutamyl carboxylase-deficient mice displayed bleeding due to the decreased activity of 
these coagulation factors. Bleeding disorder in zebrafish larvae exposed to warfarin, might 
be due to this already suggested pathways (uncarboxylated VKDPs).  In this sense, present 
result are in agreement with the reported bleeding events when warfarin therapies were 
applied to pregnant women and being more severe during the earliest developmental stages 
of the fetus (Hou, 2004). 
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Larvae exposed to high concentrations of warfarin showed a more opaque yolk sac, 
for which the causative mechanisms are still unknown. Since yolk sac, majorly a store of 
lipids, is the nutritional resource of the larvae until its exotrophic stage, the opaque 
appearance of it might be related somehow with the reported role of Pxr in the control of 
lipid metabolism, regulating the transcription of several enzymes involved in lipid 
synthesis (Moreau et al., 2007; Sui et al., 2011; Bitter et al., 2014). 
Regarding the pericardial inflammation under warfarin exposure, heart defects are 
reported in literature as an effect due to warfarin exposition, being a feature presented by 
infants carrying the WE (Hou, 2004). The cause of this pericardial inflammation is 
unknown, but could be related to the carboxylation state of different VKDPs already found 
to be expressed in heart (e.g. Mgp and growth-arrest specific 6 (Gas6)). Nevertheless, the 
inflammation present in pericardium might also account for the high mortality registered in 
these larvae. 
In addition to the already reported effects of warfarin exposure during early 
development in vertebrates, treated larvae also showed an underdevelopment of the 
swimbladder. Warfarin was associated with respiratory problems and chronic lung disease 
(Hou, 2004) which might also due to the undercarboxylation of different VKDPs. 
According to Laurance et al. (2012), the Gas6 protein, another VKDP, seems to be 
involved in the functional activation of vascular smooth cells and endothelial cells, which 
are structural cells present in blood vessels. Since Gas6 needs to be γ-carboxylated in order 
to be biologically functional, an uncarboxylation of Gas6 under warfarin exposure would 
affect the formation of the blood vessels. Interestingly, fish swimbladder development and 
inflation is tightly controlled by a complex capillary net, called rete mirabile (Smith and 
Croll, 2012). Thus, an abnormal development of the swimbladder in fish exposed to 
warfarin might be due to the abnormal development/action of this rete mirabile under Gas6 
uncarboxylation state. Mgp is also involved in vascular smooth cells homeostasis and 
particularly preventing its ectopic calcification (Schurgers et al., 2013), and its 
carboxylation state might be also altered in zebrafish exposed to warfarin. In addition to 
Gas6 and Mgp, another VKDP, Grp might be involved in an altered vascular development. 
Grp was defined as an inhibitor of vascular and valvular calcification, being involved in 
calcium homeostasis (Viegas et al., 2015). The same authors also reported that Grp 
function can be related to the prevention of calcium-induced signaling pathways and direct 
mineral binding to inhibit crystal formation and maturation. Nevertheless, additional 
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immunohistochemical and histological characterization of the vascular smooth cells, and 
particularly of the rete mirabile, are needed to address this issue. 
 
 
Zebrafish skeletogenesis under warfarin exposure and underlying pathways 
In this work we gave special emphasis on how an iduced VK deficiency by warfarin 
exposure during early development affects vertebrate’s skeletogenesis. Previous works in 
fish species reported that VK is important to bone formation and homeostasis, being 
reported that a dietary VK deficiency induce a decrease in bone mineralization, leading to 
an increase of deformities in bone (Roy and Lall, 2007). Further, Richard et al. (2014) 
demonstrated that VK dietary supplementation during early development improve bone 
development in Senegalese sole (Solea senegalensis). Opposed approach applied in 
zebrafish demonstrated that warfarin treatment caused the disruption of skeletogenesis 
through Pxr signaling pathway and γ-glutamyl carboxylation of VKDPs (Fernandez et al., 
2014). 
From studies in mammals, there is increasing evidence that VK also positively 
affects calcium balance (Weber, 2001). In vitro studies showed that while VK2 is a 
transcriptional regulator of bone marker genes in osteoblastic cells by activating the steroid 
and xenobiotic receptor (Sxr; Ichikawa et al., 2006); different VK metabolites promoted 
mineralization on human osteoblasts (Atkins et al., 2009). 
The present research work showed that skeletal development in zebrafish larvae has 
been affected when they were exposed to high levels of warfarin (25 and 125 mg L-1) 
during early developmental stages. Shorter bones, in particular endochondral bones, but 
also lower mineralization degree in endochondral and intramembranous bones have been 
reported. The observed effects are in agreement (at least partially) with the effects 
previously reported using knockout and in vitro systems. Shorter endochondral bones in 
zebrafish exposed to warfarin is in agreement with shorter long bones found in the mice 
lacking Vkorc1 (Spohn et al., 2009), while lower mineralization degree is in accordance 
with the reported lower osteoblast differentiation of osteoblastic cells treated with warfarin 
(Jeong et al., 2011). The main underlying pathways of this abnormal skeletogenesis seem 
to be related with the already proposed roles of VK: as a co-factor of Ggcx in γ-
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carboxylation reaction of VKDPs (Oldenburg et al., 2008; Spohn et al., 2009) and Pxr 
signaling activation (Ichikawa et al., 2006; Azuma et al., 2010). 
To unveil the possible skeletal specific pathways responsible for such abnormal 
skeletal development in zebrafish under warfarin exposure during early development, a 
gene specific expression analysis was performed. In this sense, expression of particular 
transcription factors (sox9a, runx2, osx), enzymes responsible of tissue mineralization 
(alp), but also proteins present in cartilage and bone extracellular matrix (col2a1a, grp1, 
mgp, and bgp) was evaluated at different sampling time points.  
Sox9a, a key TF for the commitment of osteochondroprogenitor cells, chondrogenic 
mesenchymal condensation and proper chondrocyte proliferation, differentiation, 
maturation and hypertrophic conversion (Akiyama, 2008), was found to be down-regulated 
at 3 dpf in larvae exposed to the highest level of warfarin during embryonic stage. The 
lower length in endochondral structures found at 5 and 7 dpf larvae exposed to high 
warfarin doses is in agreement with the altered commitment of osteochondroprogenitor, 
chondrogenic mesenchymal condensation, chondrocyte proliferation, differentiation and/or 
maturation suggested by the sox9a down-regulation. Altered chondrogenesis might be 
finally translated in a reduced growth of cartilage in endochondral structures such as 
meckel’s cartilage, ceratohyal and ceratobranchial arches and the ethmoid plate. In fact, 
abnormal endochondral structures development under this specific pathway has been 
previously reported as a cause of perinatal death in Sox9 heterozygous mutant mice (Bi et 
al., 2001), with cleft palate, as well as hypoplasia and bending of many skeletal structures 
derived from cartilage precursors. Furthermore, mutations in one allele of Sox9 in humans 
result in campomelic dysplasia (CD), a skeletal dysplasia characterized by sex reversal and 
skeletal malformations of endochondral bones (Mori-Akiyama et al., 2003). This is the 
first work reporting an altered gene expression of sox9a under warfarin exposure as the 
potential underlying pathway of abnormal chondrogenesis. 
Another critical TF in skeletal development analyzed was runx2. Runx2 is essential 
in the terminal differentiation of chondrocytes, a prerequisite for endochondral ossification. 
Also, during osteoblast differentiation, it plays essential roles in the commitment of 
pluripotent mesenchymal cells to the osteoblastic lineage (reviewed in Komori, 2010). 
Mundlos et al., (1997) demonstrated that mutations in runx2 are responsible to produce 
skeletal defects (such as hypoplastic clavicles, open fontanelles, Wormian bones and 
hypoplastic scapulae) in mice, similar to those found in human Cleidocranial dysplasia 
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(CCD; disorder that affect endochondral and intramembranous bone formation). Komori et 
al. (1997) showed that the disruption of runx2 results in a complete lack of bone formation 
due to maturational arrest of osteoblasts. Runx2 knockout mice showed dwarfism and had 
short legs, exhibiting also a deficit in mineralization. Interestingly, the effects on skeletal 
development under an induced VK deficiency during early development (5 and 7 dpf) do 
not seem to be due to an altered runx2 signaling pathway, as suggest by the gene 
expression analysis.  
The last TF important in skeletal development analyzed was osx. Osx is a major 
effector and essential for osteoblast differentiation, activating bone-specific genes that 
support bone formation (reviewed in Shina and Zhou, 2013). Zhou et al. (2010) reported 
that the inactivation of osx in mice after birth causes multiple skeletal phenotypes 
including lack of new bone formation, absence of resorption of mineralized cartilage, and 
defects in osteocyte maturation and function. Also, Ren and Winkler (2014) showed that 
osx ablation led to a delay of osteoblast maturation in early bone structures resulting in 
smaller and malformed structures in medaka (Oryzas latipes). Further, recently Huang and 
Olsen (2015) have reported that a conditional knockdown of osx in mice have induced 
skeletal deformities, including delayed calvarial ossification. 
In larvae exposed to high doses of warfarin during embryonic stage no significant 
differences were found at 3 dpf, in agreement with the minimal population of osteoblast 
cells found at this developmental stage. However, in larvae at 5 dpf exposed to warfarin 
during the endotrophic stage, osx was found significantly down-regulated compare with 
Control larvae. This results are in agreement with the reported lower mineralization in 
patients with a frameshift mutation in osx (Lapunzina et al., 2010) and the reported 
inhibition of osteoblastic differentiation by warfarin exposure and the osx down-regulation 
in those cells (Jeong et al., 2011). A lower expression of osx in zebrafish larvae during 
endotrophic stage is in accordance with previous reports about the key role of Osx in 
osteoblastogenesis, and coherent with the reported lower mineralization degree in 
endochondral and intramembranous structures in those warfarin exposed larvae. Thus, 
present result suggest that abnormal skeletal development in larvae exposed to warfarin 
might be due to an altered osteoblastogenesis through osx pathway and not due to altered 
runx2 signaling. 
Surprisingly, larvae exposed to warfarin during early development showed late 
effects on its skeletogenesis, being found a high percentage of larvae treated with highest 
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concentration of warfarin with a lower mineralization degree of vertebral bodies. Although 
it was not possible to evaluate the gene expression of TF in larvae from W125 group from 
the embryonic trial at 16 dpf, the analysis of the same group from endotrophic trial showed 
an up-regulation of osx and runx2. Those results are consistent with the delayed 
osteoblastogenesis process in those larvae compared with larvae from the Control group, 
where cartilage and bone cells were still in differentiation and both TFs are expressed. 
Further demonstration that chondrogenesis and osteoblastogenesis were impaired in 
zebrafish larvae exposed to warfarin during early developmental stages was made by 
analyzing the expression of other skeletal development marker genes. In this sense, tissue-
nonspecific alkaline phosphatase (tnap; and from now on alp) gene expression analysis 
showed that it was only found significantly down-regulated at 5 dpf in larvae exposed to 
highest levels of warfarin during endotrophic stages. Alp is normally induced during the 
early stage of osteoblastogenesis and participates in collagen calcification during bone 
formation (Millan, 2013). Mutations in alp caused inadequate or defective mineralization 
of the skeleton (in particular, hypophosphatasia), caused by an arrest in the propagation of 
hydroxyapatite crystals onto the collagenous ECM (reviewed in Millan, 2013). 
Furthermore, Liu et al. (2014) recently showed that alp knockout caused abnormal 
craniofacial bone development, with mice exhibiting a severely diminished bone 
mineralization. Taking this into account, present results of lower gene expression of alp at 
5 dpf is in agreement and consistent with the down-regulation of osx in the same larvae as 
well as the lower mineralization degree on endochondral and intramembranous structures.  
Genes encoding ECM proteins were also found to be differentially expressed. 
Col2a1a is expressed by chondrocytes and the main structural component of cartilage, 
providing to it shock absorbing properties and resistance to stress (Gelse et al., 2003). It 
has been suggested that the expression of the type 2 collagen gene may define and 
determine the sites and timing of chondrogenesis (Thorogood et al., 1986). Vandenberg et 
al., (1991) has reported that expression of a partially deleted human type 2 procollagen 
(col2a1) gene in transgenic mice produced a chondrodysplasia characterized by a range of 
features including short and thick limbs, and delayed mineralization of bone. Same feature 
(lower mineralization degree and short bones) have been observed in our warfarin-treated 
larvae, where a down-regulation of col2a1a was also found at 3 dpf in larvae exposed 
during embryonic stages as well as a negative correlation with warfarin concentration in 
larvae from the endotrophic strage trial at 5 dpf. Furthermore, such down-regulation is 
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consistent with the one observed in sox9a in 3 dpf larvae from the embryonic trial and the 
reported lack of expression of chondrocyte-specific markers, such as col2a1, col2a2, and 
aggrecan in mouse embryo chimeras derived from Sox9 −/− embryonic stem cells (Bi et al., 
1999). 
 Grp1 gene expression was also analyzed at 3 and 5 dpf during embryonic and 
endotrophic trials, respectively.  Grp has been reported to be expressed in several skeletal 
cell types including chondrocytes, osteocytes and osteoblasts, with chondrocytes being the 
major site of expression (reviewed in Cancela et al., 2012). Further, it was identified in the 
calcified cartilage of Adriatic sturgeon (Viegas et al., 2008), and therefore a role in 
cartilage development was initially suggested. More recently, Grp was defined as an 
inhibitor of vascular and valvular calcification, being involved in calcium homeostasis 
(Viegas et al., 2015) as other VKDPs. Viegas et al. (2015) also reported that Grp function 
can be related to the prevention of calcium-induced signaling pathways and direct mineral 
binding to inhibit crystal formation and maturation. In zebrafish, two grp isoforms (grp1 
and grp2) have been identified (Fazenda et al., 2012). Grp expression appear to be 
inversely correlated, being grp1 expressed first and remaining high during early 
development. In contrast, expression of grp2 appears later and increases in late larval and 
juvenile stages, having greater prevalence in adult tissues (Fazenda et al., 2012). In our 
analysis, grp1 was found to be down-regulated at 3 and 5 dpf, concomitant with the 
reduced chondrogenesis and osteoblastogenesis identified by double staining and 
supported by gene expression of sox9a and col2a1a.  
Finally, two VKDP’s important in skeletal development, Mgp and Bgp, were also 
analyzed at 16 dpf in Control and W125 groups from endotrophic trial. Mgp, expressed in 
several tissues and synthesized predominantly by chondrocytes has as principal function 
limiting calcification in soft tissues (reviewed in Schurgers et al., 2013). In mammals this 
protein has been associated with the differentiation and maturation of chondrocytes being a 
key regulator of fish endochondral and intramembranous ossification. Mice lacking Mgp 
developed arterial calcification which leads to blood vessel rupture, and exhibited 
inappropriate calcification of various cartilages, including the growth plate, which 
eventually led to short stature, osteopenia and fractures (Luo et al., 1997). Humans that 
lack functional Mgp showed calcification of cartilage but did not exhibit the gross vascular 
calcification observed in mice (Munroe et al., 1999). Regarding Bgp, in several teleosts, 
including zebrafish, two bgp isoforms (bgp1 and bgp2) have been identified (Laizé et al., 
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2006). Bgp1 is detected in the notochord sheath during chordacentrum formation, whereas 
bgp2 is only expressed later in association with bone formation (Bensimon-Brito et al., 
2012). Bgp is generally expressed by mature and resting osteoblasts and by hypertrophic 
chondrocytes (Bensimon-Brito et al., 2012), being suggested that is required to stimulate 
bone mineral maturation (Boskey et al., 1998). Although Pinto et al. (2001) suggested that 
Bgp in fish is associated with bone mineralization and Kavukcuoglu et al. (2009) suggested 
that this protein plays an important role in the growth of apatite crystals in bone by 
increasing the degree of carbonate substitutions; Karsenty and Ferron (2012) recently 
described Bgp as a VKDP with a broader physiological roles in the whole organism. Mice 
deficient in the osteocalcin (or bgp) gene suggested a coordinated regulation of bone mass 
or growth, energy metabolism and reproduction (reviewed in Karsenty and Ferron, 2012). 
Previous works in our lab found that while an induced VK deficiency affected mgp and 
bgp1 expression in zebrafish larvae (both of them were found up-regulated; Fernandez et 
al., 2014); bgp1 was found down-regulated in fish fed VK supplemented diets (Richard et 
al., 2014). In this work, mgp as bgp2 were not differentially expressed at 16 dpf in Control 
and W125 larvae. This could be due to the fact that in zebrafish, both bgp and mgp 
mRNAs are expressed in skeletal tissues before, during and after mineralization (Gavaia et 
al., 2006).  
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6. Conclusions 
 
This study showed that VK deficiency induced by warfarin exposure during short time at 
critical early (embryonic and endotrophic) developmental stages has a great impact on 
zebrafish development, causing growth retardation, hemorrhages, swimbladder 
underdevelopment, pericardiac inflammation, opaque appearance of yolk sac,  
skeletogenesis disruption and increase on mortality. Warfarin exposure effects were found 
developmental stage and dose dependent, being larvae exposed to 125 mg L-1 of warfarin 
during embryonic stage mimicking WE. Although these effects might be directly related to 
the impairment of VK status and the consequent decrease of the γ-carboxylation of 
different VKDPs and the lower activation of Pxr signaling pathway; new insights on the 
particular biological process (chondrogenesis and osteoblastogenesis) and their underlying 
signaling pathway (altered expression of sox9a and osx) were reported. Further, this study 
demonstrated that zebrafish is a suitable model for understanding the differential effects of 
VK deficiency when it occurs at early life stages, allowing to identify potential underlying 
mechanisms of WE, and not only regarding the abnormal bone formation. 
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7. Future perspectives 
 
Our work suggested some possible pathways affected by a VK deficiency. In this sense, 
further confirmation might be done by the use of transgenic lines, in particular those 
expressing genes associated with chondrogenesis (sox9a) or osteoblastogenesis (osx) to 
analyze in vivo the effects promoted by this VK deficiency. In addition, in situ 
hybridization procedures might give some light on the specific cell types and state 
(proliferating and/or differentiating chondrocytes and osteoblast) where abnormal 
expression of sox9a and osx took place; or western blot and inmmunohistochemistry with 
their specific antibodies for confirming abnormal gene expression has been translated in 
altered protein synthesis and/or VKDPs γ-carboxylation state. Further, since our results 
suggested that other complications are related to a deficiency in VK, it would be 
interesting to analyze the effects caused by it in the vascular tissue, brain and eyes 
development but also in other vital structures, such as the heart, through histological 
procedures. 
Finally, a wider transcriptomic analysis of larvae exposed to warfarin might give 
new insights on different biological process further affected by induced VK deficiency; 
while a Chip-seq analysis could identify the specific targeted genes by warfarin exposure 
under Pxr signaling. 
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